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1 Introduction 
1.1 Overview of neuronal development 
The central nervous system (CNS) is a massive network of neurons that 
communicate with each other through specialized cell-cell connections, called 
synapses. The brain contains billions of neurons, some forming thousands of 
synaptic connections with other neurons. The critical feature of the nervous 
system is its ability to propagate information, which requires well-controlled, 
reproducible organization of synaptic structures at precise locations. This 
suggests that explicit cellular properties must exist that create the identity and 
connectivity of each neuron in the brain.  
 In order to understand how neurons generate functional circuits, it is crucial 
to first determine where, when, and how synapse formation occurs. Our 
knowledge of how synapse formation is regulated is critical to understanding the 
underlying complexity of neural networks. This knowledge is also of great 
importance clinically, as abnormalities in synapse formation, and loss of synaptic 
connectivity are associated with numerous neurological disorders such as 
Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. 
Furthermore, understanding what molecules can promote the formation of 
synapses and/or prevent loss of connections could lead to pharmaceutical 
interventions for many neurodegenerative diseases where synaptic loss occurs.  
 Chemical synapses are cellular specializations that mediate information 
flow between neurons and their target cells. These asymmetric cellular junctions 
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are composed of both a pre- and postsynaptic terminal, separated by a synaptic 
cleft filled with fibrous material consisting of soluble and membrane bound 
proteins, carbohydrates, and varying amounts of neurotransmitters (Scheiffele, 
2003). Presynaptic terminals exist either at the ends of a terminally branched 
axon, or along the axon shaft if synapses are formed en passant. The 
presynaptic terminal is defined by the presence of synaptic vesicles (SV) 
clustered around an electron-dense region of the membrane referred to as the 
active zone. The active zone is also the physiologically defined site where 
synaptic vesicle fusion (exocytosis) and neurotransmitter release occur 
(Couteaux, 1963). The main function of the active zone is to convert a 
presynaptic action potential from the soma of the neuron into a neurotransmitter 
signal. The post-synaptic specialization contains receptors, ion channels, and 
associated proteins that together transduce the neurotransmitter signal.   
 Many of the molecular components that define the active zone are 
evolutionarily conserved and typically consist of several core proteins: RIM, 
Munc13, Piccolo, Bassoon, CASK, Velis, Mints, ELKs, and Liprins (Jin and 
Garner, 2008; Sudhof, 2012). In order for the active zone to function properly 
several events must occur. First, synaptic components are synthesized primarily 
in the neuronal cell body, and need to be transported down the axon (Hannah et 
al., 1999). This synaptic material is often present in axons well before the onset 
of synapse formation as well, to permit rapid and timely formation of synapses as 
axonal growth and extension occurs (Ziv and Garner, 2004). Piccolo and 
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Bassoon define transport vesicles that deliver active zone components to the 
presynaptic terminal (Shapira et al., 2003; Ziv and Garner, 2004). Additionally, 
the kinesin-3 family of motor proteins is specifically involved in transporting SV 
precursors (Pack-Chung et al., 2007). SVs from the reserve pool are translocated 
to the readily releasable pool, which includes SVs that are docked at the plasma 
membrane. SVs are docked through binding of SV proteins, such as Rab3a, with 
the active zone component RIM. SVs are then primed into the SNARE complex 
by RIM, Munc13, and Munc18 in preparation for Ca2+ triggered fusion (Jin and 
Garner, 2008). The core active zone components also recruit Ca2+ channels to 
the site of exocytosis, and through cell adhesion molecules position the active 
zone in apposition to the post-synaptic specialization (Sudhof, 2012).  
 Before a synapse forms, a neuron has to extend an axon outward and the 
axon needs to migrate toward the correct target. The highly dynamic tip of an 
extending axon, the growth cone, navigates by responding to a variety of 
extracellular cues and mediates migration to distant target cells where synaptic 
connections will be built (Dontchev and Letourneau, 2003). The most prominent 
and well understood guidance molecules are highly conserved and include 
netrins, slits, semaphorins, and ephrins (Dickson, 2002). These extracellular 
signals are diffusible, or anchored in the extracellular matrix or on the surface of 
guidepost cells. Guidance cues can be attractive or repulsive for the axonal 
growth cone (Kolodkin, 1996). Additionally, morphogens previously identified for 
controlling cell fate and tissue patterning, such as Wnts and Bone Morphogenic 
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Proteins, are secreted signaling molecules that act as guidance cues (Charron 
and Tessier-Lavigne, 2005). Membrane-bound receptors act as growth cone 
sensors and recognize external cues to regulate growth cone adhesion, and 
translate information through signaling molecules to the actin and microtubule 
cytoskeleton. Following guidance receptor stimulation, intracellular signaling 
cascades lead to localized cytoskeletal modifications that allow the axon to 
extend, turn or be repulsed, and ultimately navigate to a specific target (Dickson 
and Senti, 2002). In addition to their role in axon guidance, guidepost cells and 
their cues have been shown to help determine the location of synaptic sites, and 
regulate pre- and post-synaptic differentiation (Chen and Cheng, 2009). The 
ability of guidance cues to define the microenvironment for both axon guidance 
and synapse formation suggests that these events are coordinated on a 
molecular level.  
 Once the axon reaches the correct target, the synaptic machinery must be 
assembled and oriented in the correct location, and the pre- and postsynaptic 
cells must recognize each other. This is essential for proper synapse formation. 
Cell adhesion molecules (CAMs) are membrane-anchored proteins that help hold 
the pre- and postsynaptic cells together. These molecules originally were 
characterized for their function in axon outgrowth and fasciculation, but later were 
shown to be important for maintaining the integrity of the synaptic junction and 
promoting the stability of the synapse (Yamagata et al., 2003). CAMs are also 
expressed at mature synapses, where they have been shown to regulate 
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synaptic plasticity and consequently contribute to a variety of cognitive functions 
(Arikkath and Reichardt, 2008; Benson and Huntley, 2012; Hirano and Takeichi, 
2012; McGeachie et al., 2011; Sudhof, 2008). A variety of synaptic CAMs have 
been identified in the CNS and these include: neuroligins, neurexins, cadherins, 
and integrins. CAMs are classified according to the type of interaction partners 
they bind across the synaptic cleft, and are either homophillic or heterophilic. 
One of the best studied cadherins in the CNS, N-cadherin, is expressed at both 
excitatory and inhibitory synapses during development but later enriches at 
excitatory synapses (Fannon and Colman, 1996). This represents a homophilic 
synaptic CAM that participates in synapse formation, and also functions at 
mature synapses. The best-known heterophilic CAMs include the presynaptic 
neurexins and their postsynaptic partners, the neuroligins (Shen and Scheiffele, 
2010; Siddiqui and Craig, 2011). This highly diverse interaction is thought to 
provide synapse specificity (Shen and Scheiffele, 2010). It was further 
established that each partner can trigger formation of a hemisynapse, with 
neuroligins and neurexins causing pre- and post-synaptic differentiation 
respectively (Craig and Kang, 2007). Together, CAMs mediate the interaction 
between the pre- and postsynaptic cell by regulating formation, differentiation, 
and plasticity of synapses. 
 Efficient wiring of the brain requires several developmental events during 
maturation of the nervous system. Neurons send out their projections, which 
must be guided accurately and precisely over long distances to their target sites 
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(Bashaw and Klein, 2010; Kolodkin and Tessier-Lavigne, 2011). Once long-range 
navigation is complete, the neuron must transition from exclusively outgrowth to 
a combination of short-range growth and synaptogenesis (Po et al., 2010). 
Further, synapses need to form in the correct density and location (Shen and 
Scheiffele, 2010). Finally, axons must terminate their growth in a spatially and 
temporally precise manner (Feldheim and O'Leary, 2010). While these 
developmental events typically have been looked at independently of one 
another, several studies suggest that the molecular mechanisms that govern 
them are interrelated. For instance, in cultured hippocampal neurons, synapse 
assembly rapidly takes places upon axodendritic contact (Friedman et al., 2000). 
At the fly NMJ, synapses form within a tight transition period after the growth 
cone reaches its target muscle (Yoshihara et al., 1997), and new synapses are 
added at the tip of growing axons (Zito et al., 1999). Live in vivo imaging using 
developing retinal ganglion cells of zebrafish shows that synaptogenesis guides 
axon arbor growth by promoting branch extension and then stabilizing certain 
branches (Meyer and Smith, 2006). Similarly, in invertebrates and zebrafish, 
synaptic activity is linked with axon outgrowth and branching (Ben Fredj et al., 
2010; Budnik et al., 1990; Hua et al., 2005; Zhao and Nonet, 2000). Numerous 
studies in both invertebrates and vertebrates have shown that guidance cues, 
adhesion molecules, and various morphogens function in both axon guidance 
and synapse formation as well (Shen and Cowan, 2010). Despite evidence that 
the molecular mechanisms between axon outgrowth, synapse formation, and 
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termination of outgrowth are integrated during development, the identities of 
intracellular signaling proteins that coordinate these events remain unclear. 
 In the past decade, the Pam/Highwire/RPM-1 (PHR) proteins have emerged 
as key intracellular regulators of axon guidance, axon termination, and synapse 
formation. A common theme elucidated is that these proteins are likely to 
mediate the coordinated switch between axon growth and the formation of 
synapses (Po et al., 2010). Despite significant progress numerous key questions 
remain unanswered: Are there upstream regulators of PHR proteins? Is the 
localization of PHR proteins regulated? How do PHR proteins integrate 
information and regulate multiple signaling pathways? Do functionally relevant in 
vivo targets of PHR protein function remain to be discovered? This dissertation 
aims to answer some of these questions by focusing on the identification of 
several downstream molecules and pathways that mediate the function of the 
Regulator of Presynaptic Morphology 1  (RPM-1), the PHR protein in the 
nematode Caenorhabditis elegans. 
 
1.2  PHR proteins: important regulators of neuronal development 
The PHR proteins are a highly conserved family of large signaling proteins that 
have E3 ubiquitin ligase activity. PHR proteins have emerged as central 
regulators of multiple aspects of axon development.  The founding member of 
this family, human Pam (protein associated with Myc), was identified for its ability 
to interact with the proto-oncogene Myc (Guo et al., 1998). Other members of the 
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PHR family include: mouse Phr1, zebrafish Esrom, Drosophila Highwire (HIW) 
and C. elegans RPM-1. Loss-of-function mutations in PHR proteins affect the 
development of synapses and axons (Bloom et al., 2007; Culican et al., 2009; 
D'Souza et al., 2005; Lewcock et al., 2007; Schaefer et al., 2000; Wan et al., 
2000; Zhen et al., 2000). The original function of PHR proteins in neuronal 
development first emerged from three independent genetic screens looking for 
abnormal axon and/or synapse morphology. These screens elucidated C. 
elegans rpm-1 (Schaefer et al., 2000; Zhen et al., 2000) and Drosophila Highwire 
(Wan et al., 2000) as regulators of synapse development. Later, studies in 
vertebrate PHRs revealed a prominent role for Phr1 in axon navigation and 
outgrowth during development (Burgess et al., 2004; D'Souza et al., 2005).   
 Invertebrate systems have proven invaluable in our understanding of the 
PHR proteins. In C. elegans, RPM-1 regulates synapse formation in motor 
neurons (Nakata et al., 2005; Zhen et al., 2000), and mechanosensory neurons 
(Grill et al., 2007; Schaefer et al., 2000). In the mechanosensory neurons, failed 
synapse formation results in retraction of the synaptic branch (Schaefer et al., 
2000). In GABAeric motor neurons, rpm-1 mutants show fewer presynaptic 
specializations, and synaptic organization is abnormal (Zhen et al., 2000). These 
neurons also have abnormal presynaptic terminals with aggregated active zones 
(Zhen et al., 2000). rpm-1 mutants have severe axon termination defects in both 
the motor neurons and mechanosensory neurons (Grill et al., 2007; Opperman 
and Grill, 2014; Schaefer et al., 2000). Axon termination defects occur when 
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axons grow past precise anatomical locations where outgrowth is normally 
halted.  
Highwire (Hiw) regulates axon branching, axon length, and synapse 
formation of fly motor neurons (Collins et al., 2006; Wan et al., 2000). In hiw 
mutants, long-range motor axon pathfinding is normal, but excessive axon 
branching occurs, and is accompanied by abnormally long axonal processes 
(Wan et al., 2000). Synapse formation is also abnormal with higher numbers of 
glutamatergic presynaptic terminals forming, but with drastically reduced size 
(Wan et al., 2000). While these synapses are ultrastructurally normal, they have 
impaired synaptic transmission. The extensive increase in motor axon length in 
hiw mutants suggests that these animals have defects in axon termination that 
accompany synapse formation defects. This is further supported by recent work 
in fly sensory neurons that shows Hiw regulates axon termination (Kim et al., 
2013).  
Despite differences in the presentation of synapse formation defects in 
worms and flies lacking PHR protein function, both HIW and RPM-1 function cell-
autonomously in motor neurons to regulate axon termination and synapse 
formation, often in the same cell (Opperman and Grill, 2014; Schaefer et al., 
2000; Zhen et al., 2000). Similarly, RPM-1 functions cell autonomously in 
mechanosensory neurons to regulate synapse formation and axon termination in 
individual cells (Opperman and Grill, 2014; Schaefer et al., 2000). These results 
are consistent with RPM-1 being localized to distinct subcellular compartments, 
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the mature axon tip, and the presynaptic terminal in both motor neurons and 
mechanosensory neurons (Abrams et al., 2008; Opperman and Grill, 2014; Zhen 
et al., 2000). Studies focused on the PLM mechanosensory neurons, which show 
severe and highly frequent axon termination defects in rpm-1 mutants, have 
shown that once termination fails in rpm-1 mutants that Slit and Netrin are the 
attractive guidance cues that facilitate excess axon outgrowth (Li et al., 2008). 
Very little is known about the extracellular cues that trigger PLM axon 
termination, but a recent study has suggested a modest role for two Wnts, LIN-44 
and EGL-20 (Tulgren et al., 2014).  
With regard to vertebrates, mice lacking Phr1 function have motor neurons 
with synapse formation defects (Bloom et al., 2007; Burgess et al., 2004). In 
Phr1-/- mice, the phrenic nerve fails to properly innervate the diaphragm. This 
defect coupled to the possibility of impaired synaptic function is thought to 
explain why these mice die shortly after birth. Similar to the synaptic defects 
observed in both Hiw and rpm-1 mutants, presynaptic terminal morphology is 
severely disrupted in the motor neurons of mice lacking Phr1 (Burgess et al., 
2004). More specifically, the size of the presynaptic terminals is reduced, and 
orphan presynaptic terminals are present that lack postsynaptic partners (Bloom 
et al., 2007; Burgess et al., 2004). Further, NMJs made by the phrenic nerve 
display abnormally long terminals that could suggest defects in axon termination 
or axonal pruning.  
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 While early studies on invertebrate PHR proteins identified roles in 
synapse formation and axon termination, later studies on vertebrate PHRs 
demonstrated a prominent role for PHR proteins in axon guidance and outgrowth 
in both the peripheral and central nervous system. In mice with targeted 
disruption of Phr1, there is a severe reduction of axon tracts in the brain, as well 
as an overall decrease of neurites in the cerebral cortex (Bloom et al., 2007).  
Motor axon guidance and extension is also impaired in the motor neurons in the 
hind limb (Lewcock paper 2007). In Zebrafish Esrom mutants, bundling of retinal 
axons is disrupted and incorrect targeting of these axons causes ectopic 
arborization (D'Souza et al., 2005). These navigation defects are likely to result in 
part from abnormal microtubule dynamics (Hendricks and Jesuthasan, 2009). 
While axon guidance and extension defects are prominent in Phr1-/- mice, the 
sensory neurons of these animals do have axon termination defects in the 
periphery and in the spinal column (Burgess et al., 2004; Holland et al., 2011; 
Lewcock et al., 2007). Thus, PHR proteins play a conserved functional role in 
axon termination from worms to mammals, but neuronal context and the 
extracellular environment seem likely to dictate whether a PHR protein will figure 
more prominently in axon extension and guidance versus axon termination. 
 Systemic defects in axon guidance and extension are not observed in 
invertebrates lacking PHR protein function. However, results from the worm on 
the AVM mechanosensory neuron showed that RPM-1 does regulate axon 
guidance in the context of sensitizing backgrounds, such as loss of function in 
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the unc-5 Netrin receptor or the sax-3 Robo receptor (Li et al., 2008). Analysis of 
double mutants of rpm-1 and the active zone regulator syd-2/liprin showed that 
RPM-1 not only regulates axon termination, but can affect axon extension in 
motor neurons (Opperman and Grill, 2014). Thus, while RPM-1 is not a primary 
regulator of axon extension and guidance, it does function in these processes. 
 Loss of PHR protein function results in varied combinations of defects in 
axon guidance and extension, axon termination, and synapse formation during 
maturation of the nervous system in different organisms. This diverse range of 
phenotypes is likely to result from PHR proteins regulating multiple signaling 
pathways as well as the cell type, developmental stage, and surrounding 
extracellular cues that a given neuron experiences. Nonetheless, a likely unifying 
theme for these phenotypic observations is that PHR proteins regulate the 
transition between important events in neuronal development (Po et al., 2010).  
 
1.3 PHR proteins function as signaling hubs 
PHR proteins are gigantic proteins with multiple conserved domains (Figure 1-
1A), which lends to their involvement in multiple aspects of neuronal 
development. PHR proteins contain an RCC1-like domain, two PHR protein-
specific repeats, a Myc-binding region (that is only partially conserved in RPM-1 
and Hiw), and a RING-H2 zinc finger domain that confers E3 ubiquitin ligase 
activity (Guo et al., 1998; Wan et al., 2000; Zhen et al., 2000). Many of the loss-
of-function alleles in both vertebrate and invertebrate PHR mutants encode  
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premature stop codons or missense mutations that affect the RCC1-like and 
RING-H2 domains, highlighting the functional importance of these domains 
(D'Souza et al., 2005; Wan et al., 2000; Zhen et al., 2000). Recently, another 
conserved domain called the RAE-1 binding domain was also discovered (Grill et 
Figure 1-1. PHR protein signaling in vertebrates and invertebrates. 
(A) Diagram of the conserved protein domains of the PHR proteins Pam, Phr1, Esrom, HIW, 
and RPM-1: RCC1 like domain (RLD), two PHR family specific domains (PHR), RAE-1 binding 
domain (RBD), Myc binding domain (MBD), and RING-H2 ubiquitin ligase domain (RING). (B) 
PHRs function through both positive and negative signaling mechanisms to regulate different 
aspects of neuronal development. PHRs interact with the F-box proteins (FSN-
1/DFsn/Fbxo45) to downregulate DLK/Wallenda activity through ubiquitination (RPM-
1/HIW/Phr1). This negative regulation of DLK/Wallenda results in inhibition of p38 and JNK 
MAP kinase signaling. PHRs also ubiquitinate NMNAT/NMNAT2 (HIW/Phr1), and TSC which 
inhibits mTOR signaling (Phr1/Pam/Esrom).  PHR proteins have also been shown to bind to 
Myc (Pam), RAE-1/DRae-1 (RPM-1/HIW), GLO-4 (RPM-1), ANC-1 (RPM-1), KCC2 (PAM), 
and Adenylate cyclase (Phr1). They also associate with polymerized microtubules and F-actin 
(Pam/Phr1/Esrom). Dashed lines indicate unknown domain of binding, while connected lines 
indicate direct binding to a specific domain.  
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al., 2012). Over the past decade, a combination of genetic and biochemical 
evidence has revealed that the PHR proteins exert both positive and negative 
activity through several functionally conserved signaling pathways (Figure 1-1B). 
Because PHR proteins, and in particular RPM-1, function through such a diverse 
array of downstream signaling activities it has prompted the proposal that PHR 
proteins function as intracellular signaling hubs that regulate neuronal 
development (Cherra and Jin, 2015)  
 Previous studies in C. elegans, Drosophila, and mice have shown that PHR 
proteins function as E3 ubiquitin ligases that negatively regulate p38 and JNK 
MAP kinase signaling (Collins et al., 2006; Klinedinst et al., 2013; Lewcock et al., 
2007; Nakata et al., 2005; Yan et al., 2009). PHRs interact with the FSN-
1/DFsn/Fbxo45 F-box proteins, and function as a complex to ubiquitinate and 
degrade the DLK/Wallenda MAP3K (Liao et al., 2004; Saiga et al., 2009; Wu et 
al., 2007). By regulating DLK, PHR proteins impact p38 and JNK MAP kinase 
signaling cascades (see Figure 1-1B). 
 The ubiquitin ligase function of the PHR proteins not only regulates MAP 
kinase cascades, but also affects mTOR signaling via ubiquitination and 
degradation of the Tuberous Sclerosis Complex (Han et al., 2012; Han et al., 
2008; Murthy et al., 2004). PHR control of the activity and levels of the axon 
survival molecule NMNAT takes place through ubiquitination as well, and this 
regulation likely balances axonal maintenance and degeneration (Babetto et al., 
2013; Xiong et al., 2012). 
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 Ubiquitin ligase activity is not the sole biochemical function of the PHR 
proteins. PHR proteins bind to several proteins that are not targeted for 
ubiquitination and degradation. These PHR binding proteins include Myc (Guo et 
al., 1998), a Rab GEF GLO-4 (Grill et al., 2007), a microtubule binding protein 
RAE-1 (Grill et al., 2012), and the Nesprin ANC-1 (Tulgren et al., 2014) (see 
Figure 1-1B). Further, the RCC1-like domain of Phr1 inhibits adenylate cyclase 
(Scholich et al., 2001), and promotes the activity of the neuronal K+CL- 
transporter KCC2 (Garbarini and Delpire, 2008). PHR proteins also associate 
with polymerized microtubules (Lewcock et al., 2007) and polymerized F-actin 
(Pierre et al., 2008). Together, these studies show that through both positive and 
negative signaling, PHR proteins function in variety of processes including: 
endosomal trafficking or formation (Grill et al., 2007), receptor trafficking and 
endocytosis (Holland et al., 2011; Li et al., 2008; Park et al., 2009), microtubule 
dynamics (Hendricks and Jesuthasan, 2009; Lewcock et al., 2007), and gene 
transcription (Collins et al., 2006; Han et al., 2008; Murthy et al., 2004; Nakata et 
al., 2005). 
 
1.4 Postdevelopmental function of PHR proteins  
In addition to regulating the developing nervous system, the PHR proteins were 
recently shown to function in mature, adult neurons. Axon degeneration occurs 
frequently in many types of neurodegenerative diseases and in injuries to axons 
as a result of trauma (Coleman and Perry, 2002; Raff et al., 2002). This leads to 
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loss of neuronal function through an apoptosis-independent mechanism. 
Research on Wallerian degeneration, a process that involves the degeneration of 
distal axons after nerve injury, is the simplest and fastest physiological model of 
axon degeneration available (George and Griffin, 1994). Using this model, 
inhibition of the ubiquitin proteasome system was shown to profoundly delay 
axon degeneration (Zhai et al., 2003). However, it remained unclear which E3 
ubiquitin ligases impacted axon degeneration. A recent study showed that Hiw 
promotes Wallerian degeneration by negatively regulating the NAD+ biosynthetic 
enzyme Nmnat (Xiong et al., 2012).  Previous studies on Wallerian degeneration 
established a role for NMNAT in protecting severed axons from degeneration 
(Coleman and Perry, 2002; Feng et al., 2010b; Zhai et al., 2008). Because Hiw 
targets ectopically expressed NMNAT2 from the mouse, this function was 
potentially conserved (Xiong et al., 2012). Indeed, Phr1 was shown to be a key 
component of the axonal degeneration program that regulates the availability of 
NMNAT2 (Babetto et al., 2013). Increased levels of NMNAT2 in Phr1 genetically 
ablated mice delays axon degeneration and leads to long-term preservation of 
peripheral and central nervous systems axons and synapses (Babetto et al., 
2013). In addition to targeting NMNAT, Hiw and Phr1 also downregulate the 
MAP3K Wnd/DLK as a secondary mechanism to promote Wallerian 
degeneration (Miller et al., 2009; Xiong and Collins, 2012; Xiong et al., 2012). 
Notably, Wnd function is not required for Hiw to regulate Nmnat, as both Wnd 
and Nmnat protect axons independently of one another (Xiong et al., 2012). 
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 Injury studies in flies revealed that neurons regenerate faster when excess 
Dlk/Wnd signaling is present (Xiong et al., 2010). In worms, DLK-1 is necessary 
and sufficient for axon regeneration in motor neurons and mechanosensory 
neurons following injury (Hammarlund et al., 2009; Yan et al., 2009). Importantly, 
DLK functions as a conserved regulator of axon regeneration in mammals (Itoh 
et al., 2009; Shin et al., 2012). Overall, this body of work suggests that PHR 
proteins regulate a core axon regeneration and degeneration program that 
balances axon survival and loss (Babetto et al., 2013).  
 Axonopathy is a major component of many neuropathies and neurological 
diseases, which remain largely untreatable. Mammalian Phr1 is a potentially 
attractive therapeutic target for pharmacological agents that would broadly 
reduce axon degeneration and/or improve axon regeneration. The challenge will 
be to develop specific inhibitors of the PHR ubiquitin ligase complex. While drugs 
targeting global protein degradation have been discovered, efforts on targeting 
enzymes upstream of the proteasome, such as E3 ubiquitin ligases, remain in 
their infancy (Zhao and Sun, 2013). 
 
1.5  The PHR ubiquitin ligase complex 
Negative regulation of the MAP3K Dlk/Wnd by PHR proteins is mediated by a 
conserved biochemical mechanism. PHR proteins function through an ubiquitin 
ligase complex that includes an F-box protein: FSN-1 in C. elegans (Liao et al., 
2004), DFsn in Drosophila (Wu et al., 2007), and Fbxo45 in mammals (Saiga et 
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al., 2009) (see Figure 1-1B). Despite this progress, the large size of the PHR 
proteins has hindered structure-function analysis, and we know relatively little 
about how the PHR proteins interact with these F-box proteins. Some progress 
was made with the discovery that Fbxo45 binds to the same very large region in 
human PAM where Myc binds, which is referred to as the Myc binding domain 
(MBD) (Saiga et al., 2009) (see Figure 1-1A). The MBD of Phr1 contains a 
conserved N-terminal region and a C-terminal region that is not conserved. 
Proteomic screens for proteins that bind to the invertebrate PHRs have not 
identified Myc (Grill et al., 2007; Tian et al., 2011). This suggests that Myc most 
likely binds to the C-terminal region of the MBD that is only present in vertebrate 
PHR proteins. In one chapter of this dissertation, we focus on a detailed 
structure-function analysis of RPM-1 and FSN-1. We provide evidence that the 
conserved N-terminal portion of the MBD in RPM-1 mediates binding to FSN-1. 
More importantly, our biochemical and genetic analysis has led to the 
identification of an in vivo inhibitor of the RPM-1/FSN-1 ubiquitin ligase complex. 
This represents the first inhibitor of a PHR ubiquitin ligase complex that has been 
identified to date. On a pharmacological level, a small molecule that specifically 
blocks the formation or function of the PHR ubiquitin ligase complex might be 
valuable for improving axon regeneration following trauma, or slowing the onset 
of axon degeneration in a range of neurodegenerative diseases.  
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1.6  C. elegans RPM-1 
As previously mentioned, C. elegans RPM-1 was first identified in independent 
genetic screens looking for axon/synaptic morphology defects (Schaefer et al., 
2000; Zhen et al., 2000). In one of these studies, RPM-1 was also shown to 
regulate axon termination. Subsequent work has identified an array of 
downstream signaling mechanisms that mediate RPM-1 function in axon 
termination and synapse formation (Figure 1-2). RPM-1 forms an SCF-like 
ubiquitin ligase complex with the F-box protein FSN-1 (Liao et al., 2004), and 
through the RING-H2 domain ubiquitinates the MAP3K DLK-1 to target it for 
proteasomal degradation (Nakata et al., 2005). DLK-1 is the most upstream 
kinase in a p38 MAP kinase cascade, and a combination of genetic suppressor 
experiments and biochemistry showed that RPM-1 negatively regulates this 
pathway (Nakata et al., 2005). Proteomic screens for RPM-1 binding proteins 
have identified several molecules and pathways that mediate RPM-1 function. 1) 
GLO-4, a guanine nucleotide exchange factor that regulates GLO-1, a Rab 
GTPase (Grill et al., 2007). RPM-1 positively regulates this pathway to regulate 
late endosome trafficking or biogenesis (Grill et al., 2007). 2) The microtubule 
binding protein RAE-1, which colocalizes with RPM-1 at the presynaptic 
terminals of motor neurons (Grill et al., 2012). This finding established a novel 
post-mitotic function for RAE-1 in neuronal development. 3) The Nesprin ANC-1, 
which functions in a non-canonical β-catenin pathway (Tulgren et al., 2014). This 
study highlights an unexpected mechanism by which RPM-1 functions, as it is  
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the first genetic link between RPM-1 and a pathway that is regulated by 
extracellular signals, such as Wnts (Tulgren et al., 2014). 4) A PP2C family 
phosphatase, PPM-2, was also identified as an RPM-1 binding protein in this 
proteomic screen. Chapter two of this dissertation will describe our work 
characterizing how PPM-2 binds to RPM-1 and mediates RPM-1 function in axon 




Figure 1-2. RPM-1 signaling in C. elegans. 
RPM-1 functions through an array of downstream signaling mechanisms to regulate neuronal 
development. It positively regulates the GLO-4 pathway consisting of the GEF GLO-4 and the 
Rab GTPase GLO-1. Additionally it positively regulates the Nesprin ANC-1, which functions in 
a non-canonical β-catenin pathway with BAR-1. RPM-1 forms an SCF-like ubiquitin ligase 
complex with the F-box protein FSN-1 and together they target the MAP3K DLK-1 for 
proteasomal degradation via ubiquitination. In this way, RPM-1 negatively regulates the DLK-1 
pathway, which consists of the MAP3K DLK-1, the MAP2K MKK-4, the p38 MAP kinase PMK-
3, the MAPKAP kinase MAK-2, and the C/EBP bZip factor (CEBP-1). The PP2C phosphatase 
PPM-1 negatively regulates the DLK-1 pathway, most likely at the level of PMK-3. RPM-1 also 
binds to the microtubule binding protein RAE-1. The small box in the RBD represents a 
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1.7  PP2C family phosphatases 
Several studies suggest that MAP kinases are negatively regulated by 
phosphatases including MAP kinase-specific phosphatases, and broad-acting 
Protein Phosphatase 2C (PP2C)/ Protein Phosphatase Mg/Mn dependent (PPM) 
family phosphatases (Bermudez et al., 2010; Lu and Wang, 2008; Shi, 2009). 
While MAP kinases are known to function in neurons (Ji et al., 2009; Samuels et 
al., 2009), very little is known about the negative regulatory mechanisms that 
control MAP kinase signaling pathways in vivo. I have already touched on PHR 
proteins functioning as ubiquitin ligases to regulate MAP kinase cascades in vivo. 
Here, I will discuss what is known about PP2C phosphatase function in vivo in 
the nervous system. 
PP2C/PPM family phosphatases are single subunit enzymes with 
serine/threonine phosphatase activity. Biochemical experiments in vitro and in 
mammalian cell culture systems have shown that PP2Cα and PP2Cβ can 
dephosphorylate and negatively regulate MKKKs, MKKs, and MAPKs (Hanada et 
al., 2001; Takekawa et al., 1998). Yeast Hog1, the homolog of the p38 MAPK, is 
negatively regulated by homologs of PP2Cα (Jacoby et al., 1997; Maeda et al., 
1994; Nguyen and Shiozaki, 1999; Saito and Tatebayashi, 2004). Additionally, 
PP2Cα functions in mammalian neurons to control calcium flux (Li et al., 2005), 
which suggests that PPC2 phosphatases could affect neuronal function. We 
recently provided evidence that PPM-1, a PP2C phosphatase homologous to 
human PP2Cα (PPM1A) and PP2Cβ (PPM1B), acts as a negative regulatory 
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mechanism to inhibit the DLK-1 pathway (Tulgren et al., 2011). This negative 
regulation is most likely the result of PPM-1 acting at the level of the p38 MAPK 
PMK-3 (Figure 1-2). In doing so, PPM-1 functions cell autonomously in the motor 
neurons and mechanosensory neurons to regulate axon termination and synapse 
formation. This study provided the first evidence that PP2C phosphatases 
regulate neuronal development in vivo.  
 As mentioned earlier, another PP2C phosphatase, PPM-2, was identified 
in a proteomic screen for RPM-1 binding proteins. Experiments performed as 
part of my dissertation work will show that PPM-2 binds to RPM-1, is positively 
regulated by RPM-1, and functions downstream of RPM-1 to regulate axon 
termination and synapse formation. Further, I will present biochemical and 
genetic data suggesting that PPM-2 functions to directly dephosphorylate and 
inhibit DLK-1. An implication of our findings is that RPM-1 acts as an ubiquitin 
ligase to regulate long-term stability and turnover of DLK-1, and uses PPM-2 as 
an independent mechanism to inhibit DLK-1 activity.  These results point towards 
the PHR proteins as particularly sophisticated regulators of DLK-1 signaling. 
 
1.8  The MLK-1 MAP Kinase Pathway 
In C. elegans, RPM-1 regulates neuronal development by inhibiting the MAP 
kinase pathway composed of DLK-1, MKK-4, PMK-3, MAK-2, and CEBP-1 
(Nakata et al., 2005; Yan et al., 2009). Studies in worms, flies, and mice have 
shown that DLK/Wallenda kinase is required for axon regeneration (Hammarlund 
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et al., 2009; Shin et al., 2012; Xiong et al., 2010; Yan et al., 2009). A second 
MAP kinase pathway, composed of MLK-1, MEK-1 and the KGB-1 JNK, is also 
required for axon regeneration in worms (Nix et al., 2011). The role of the MLK-1 
pathway in neuronal development remains unknown. This dissertation describes 
our study showing that the MLK-1 pathway regulates synapse formation and 
axon termination. The MLK-1 pathway, like the DLK-1 pathway, is negatively 
regulated by RPM-1. Unlike axon regeneration, our results indicate that the MLK-
1 pathway plays a secondary role to the DLK-1 pathway in neuronal 
development. We also explore whether the PP2C phosphatases PPM-1 and 
PPM-2 regulate the MLK-1 pathway. These findings further expand our 
understanding of the signaling mechanisms that mediate RPM-1 function in 
neurons.  
 
1.9  The nematode C. elegans: an ideal model system for studying 
neuronal development in vivo 
In the later half of the twentieth century, Sydney Brenner introduced a free-living 
microscopic nematode, C. elegans, as a genetic model to study development 
and neurobiology (Brenner, 1974). For this work, Dr. Brenner was awarded the 
Nobel Prize. Today, C. elegans is used to study a plethora of biological 
processes including apoptosis, cell signaling, gene regulation, metabolism, 
aging, and sex determination (Riddle et al., 1997). Several discoveries have 
highlighted the value of the worm for understanding the conserved molecular and 
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genetic mechanisms underlying several diseases, such as type 2 Diabetes (Ogg 
et al., 1997), depression (Ranganathan et al., 2001), Alzheimer’ disease 
(Sundaram and Greenwald, 1993), and Parkinson’s disease (Berkowitz et al., 
2008; Caldwell and Caldwell, 2008; Locke et al., 2008). Comparison of the 
complete worm and human genome have also revealed that a large number of 
genes and pathways, particularly those relevant for function of the nervous 
system, are conserved between humans and C. elegans (Bargmann, 1998; 
Consortium, 1998; Lander et al., 2001; Venter et al., 2001)  
 C. elegans is a powerful model system for several reasons. It is easy to 
cultivate due to its simple diet of bacteria, it can reproduce as a self-fertilizing 
hermaphrodite facilitating genetic analysis, and the worm has a rapid life cycle 
developing from egg to adult within 3 days. C. elegans has a transparent body, 
which allows for simple visualization of numerous features in the living animal, a 
characteristic that is highlighted by the Nobel Prize winning work of Dr. Martin 
Chalfie (Chalfie et al., 1994). Of particular relevance to neurobiology, C. elegans 
is the only metazoan in which the connectome is known, i.e. electron microscopy 
has been used to map the complete network of chemical and electrical synapses 
that connect all 302 neurons of the worm nervous system (White, 1986). This 
work also showed that the position and connectivity of neurons in the worm is 
invariant. Further, a majority of the known molecules that regulate neuronal 
development in the worm are conserved with higher organisms (Margeta et al., 
2008). Along with powerful genetics, rapid transgenics, and a growing 
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biochemical toolkit, C. elegans has become a tremendous model system for 
studying multiple aspects of biology, but most importantly for our lab and this 
dissertation, studying the development of the nervous system.  
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2 RPM-1 Uses Both Ubiquitin Ligase and Phosphatase-Based 
Mechanisms to Regulate DLK-1 during Neuronal 
Development 
Content adapted from published article: Baker ST, Opperman KJ, Tulgren 
ED, Turgeon SM, Bienvenut W, Grill B (2014) RPM-1 Uses Both Ubiquitin 
Ligase and Phosphatase-Based Mechanisms to Regulate DLK-1 during 
Neuronal Development. PLoS Genet 10(5): e1004297. 
doi:10.1371/journal.pgen.1004297 
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2.1 Introduction 
As a neuron develops, its axon must execute several important tasks. Initially, 
the axon extends toward target cells by sensing extracellular guidance cues. 
Upon reaching its target, the axon detects guidepost signals and makes 
presynaptic connections with its postsynaptic partner(s) to form synapses (Jin 
and Garner, 2008; Kolodkin and Tessier-Lavigne, 2011; O'Donnell et al., 2009). 
At some point during these events, an axon must terminate outgrowth in a 
spatially and anatomically accurate manner. At present, we know little about how 
axon termination is governed, and even less about how this process is integrated 
with synapse formation.  
 While axon extension, synapse formation, and termination of axon 
outgrowth are often analyzed individually, there is substantial evidence 
suggesting that these events are coordinated and integrated during development. 
Elegant live imaging studies using developing retinal ganglion cells (RGC) in 
Xenopus and zebrafish showed there is a tight temporal and spatial link between 
axon outgrowth and synapse formation (Alsina et al., 2001; Ben Fredj et al., 
2010; Meyer and Smith, 2006; Ruthazer et al., 2006). In cultured neurons, 
synaptogenesis proceeds rapidly upon contact between an actively growing axon 
and its dendritic partner (Ahmari et al., 2000; Friedman et al., 2000). At the 
Drosophila neuromuscular junction (NMJ), synapse formation displays tight 
temporal linkage with axon outgrowth (Yoshihara et al., 1997), and new 
synapses are formed at the terminal tips of growing axons (Zito et al., 1999). 
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Studies in C. elegans, Drosophila, and zebrafish have also shown a link between 
synaptic activity, and axon outgrowth and branching (Ben Fredj et al., 2010; 
Budnik et al., 1990; Hua et al., 2005; Zhao and Nonet, 2000). Finally, studies in 
invertebrate and vertebrate systems have shown that morphogens, axon 
guidance cues, and cell adhesion molecules function in both axon outgrowth and 
synapse formation (Shen and Cowan, 2010). This functional promiscuity is likely 
to reflect, in part, that extracellular signals take on different roles during 
development, and in different types of neurons. However, some of these 
observations also highlight a potential role for extracellular signals in coordinating 
axon outgrowth and termination with synapse formation. Two cases of particular 
note from C. elegans where guidance cues regulate both axon guidance and 
synapse formation in a single type of neuron are the role of UNC-6 (Netrin) in the 
RIA and AIY neurons (Colon-Ramos et al., 2007), and studies on UNC-6 and 
Wnts on the DA9 neuron (Hedgecock et al., 1990; Klassen and Shen, 2007; 
Poon et al., 2008). 
 At present, the identity of intracellular signaling proteins that may 
coordinate axon outgrowth, synapse formation, and termination of outgrowth 
remain unclear. Nonetheless, such coordinators would be likely to meet several 
criteria. 1) They would need to be evolutionarily conserved, and function in 
multiple events during the development of an individual neuron. 2) They would 
need to be signaling molecules that function intracellularly and cell 
autonomously. 3) Their activity would need to be regulated by upstream, 
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presumably extracellular, signals. 4) They would need to regulate multiple 
downstream signaling pathways, and do so both positively and negatively. 5) 
They would need to regulate downstream signaling pathways in a relatively 
precise and accurate manner, most likely to control both gene transcription and 
short-term/local signaling events. 
 Members of the PHR protein family meet several of these criteria, and 
have been put forward as candidate molecules that may coordinate different 
events during neuronal development (Li et al., 2008; Po et al., 2010). The PHR 
proteins are highly conserved with a single family-member in worms, flies, fish, 
mice, and humans (Po et al., 2010). The PHR proteins function in a range of 
developmental events playing roles in axon extension (Bloom et al., 2007; 
Burgess et al., 2004; Lewcock et al., 2007), axon guidance (Bloom et al., 2007; 
Culican et al., 2009; D'Souza et al., 2005; Hendricks and Jesuthasan, 2009; Li et 
al., 2008; Shin and DiAntonio, 2011), axon termination (Kim et al., 2013; 
Lewcock et al., 2007; Schaefer et al., 2000), and synapse formation (Burgess et 
al., 2004; Schaefer et al., 2000; Wan et al., 2000; Zhen et al., 2000). Importantly, 
studies on the mechanosensory neurons of C. elegans and the motor neurons of 
Drosophila have shown that the PHR proteins function cell autonomously to 
regulate synapse formation, as well as axon termination and branching in 
individual neurons (Schaefer et al., 2000; Wan et al., 2000). The functional 
importance of the PHR protein family is further highlighted by studies showing 
that they regulate axon regeneration (Hammarlund et al., 2009; Xiong et al., 
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2010), axon degeneration (Babetto et al., 2013; Xiong et al., 2012), and aversive 
long-term memory (Huang et al., 2012). 
 While our picture of the mechanism for PHR protein function is 
incomplete, previous studies have established that PHR proteins regulate 
multiple intracellular signaling pathways both negatively and positively (Collins et 
al., 2006; Grill et al., 2007; Grill et al., 2012; Lewcock et al., 2007; Murthy et al., 
2004; Nakata et al., 2005; Pierre et al., 2004; Scholich et al., 2001; Tian et al., 
2011; Yan et al., 2009). Through these signaling mechanisms, the PHR proteins 
function in late endosome/lysosome trafficking or formation (Grill et al., 2007), 
receptor trafficking and endocytosis (Holland et al., 2011; Li et al., 2008; Park et 
al., 2009), microtubule dynamics (Hendricks and Jesuthasan, 2009; Lewcock et 
al., 2007), and gene transcription (Collins et al., 2006; Han et al., 2008; Murthy et 
al., 2004; Nakata et al., 2005). The human PHR protein called Protein Associated 
with Myc (Pam) or Myc binding protein 2 (MYCBP2) also binds to F-actin (Pierre 
et al., 2008), which suggests a further link between the PHR proteins and the 
cytoskeleton. While our knowledge of how the PHR proteins function has grown 
rapidly, it remains unclear if the PHR proteins have the potential to meet two 
important criteria as candidate coordinators of neuronal development. Are the 
PHR proteins regulated by upstream signals that are triggered by extracellular 
guidance cues, adhesion molecules, or morphogens? Do the PHR proteins have 
the potential to precisely and accurately control the signaling pathways they 
regulate?  
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 An important, conserved function of the PHR proteins is to ubiquitinate 
and negatively regulate MAP kinase kinase kinase (MAP3K) signaling. The 
ubiquitin ligase activity of the PHR proteins requires an F-box protein called F-
box Synaptic protein 1 (FSN-1) in C. elegans and Drosophila (Liao et al., 2004; 
Wu et al., 2007) and Fbxo45 in mice (Saiga et al., 2009). One MAP3K target of 
the PHR proteins is DLK (Collins et al., 2006; Huntwork-Rodriguez et al., 2013; 
Lewcock et al., 2007; Nakata et al., 2005). Mammalian DLK (also called 
MAP3K12) has functional orthologs in C. elegans (DLK-1), and Drosophila 
(Wallenda). PHR proteins also use ubiquitination to negatively regulate the TSC 
complex (Han et al., 2008; Murthy et al., 2004) and NMNAT (Babetto et al., 2013; 
Xiong et al., 2012).  
 DLK plays an important and conserved function in neuronal development 
by regulating synapse formation, axon extension, and termination of axon 
outgrowth (Collins et al., 2006; Eto et al., 2010; Grill et al., 2007; Hirai et al., 
2006; Nakata et al., 2005; Wang et al., 2013). In mature neurons, DLK is critical 
for axon regeneration (Hammarlund et al., 2009; Itoh et al., 2009; Shin et al., 
2012; Watkins et al., 2013; Xiong et al., 2010; Yan et al., 2009), and also 
functions in axon degeneration (Ghosh et al., 2011; Miller et al., 2009).  
 Progress has been made in understanding how DLK is regulated. Studies 
using cell lines and in vitro biochemical methods have shown that DLK is 
phosphorylated, self-dimerizes, and autophosphorylates (Daviau et al., 2009; 
Mata et al., 1996; Nihalani et al., 2001). JNK Interacting Proteins (JIP) bind to 
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DLK potentially acting as scaffolds to regulate DLK activity or localization (Ghosh 
et al., 2011; Nihalani et al., 2001). In Drosophila, the cytoskeletal regulatory 
protein Spectraplakin inhibits DLK (Valakh et al., 2013). Pharmacological studies 
have suggested that the phosphatase calcineurin (Mata et al., 1996) and the 
kinase Src (Daviau et al., 2009) may regulate DLK, but evidence that these 
molecules regulate DLK in neurons is absent. Finally, work in C. elegans has 
shown that calcium signaling functions upstream of DLK-1 (Ghosh-Roy et al., 
2010) to regulate binding of a short, inhibitory isoform of DLK-1 (DLK-1S) to full 
length DLK-1 (DLK-1L) (Yan and Jin, 2012).  
 Here, we show that RPM-1 (the C. elegans PHR protein) employs a 
phosphatase-based mechanism to inhibit DLK-1. Using a combination of 
proteomics and genetics, we show that RPM-1 binds to and positively regulates 
Protein Phosphatase Magnesium/Manganese dependent 2 (PPM-2), a member 
of the PP2C phosphatase family. We provide genetic, transgenic, and 
biochemical evidence showing that PPM-2 negatively regulates DLK-1L by direct 
dephosphorylation at a specific serine residue that is implicated in binding to 
DLK-1S. Our findings demonstrate that RPM-1 harnesses two independent 
mechanisms to negatively regulate DLK-1, ubiquitination and PPM-2 
phosphatase activity. These results suggest that RPM-1 may function through 
ubiquitin ligase activity to regulate long-term DLK-1 signaling and through the 
phosphatase PPM-2 to regulate short-term/local DLK-1 signaling. Thus, PHR 
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2.2.1 Identification of PPM-2 as an RPM-1 binding protein 
To better understand the mechanism of how RPM-1 regulates neuronal 
development, we previously purified RPM-1 and used mass spectrometry to 
identify RPM-1 binding proteins (Grill et al., 2007). In brief, a fusion protein of 
RPM-1 and GFP (RPM-1::GFP) was transgenically expressed in C. elegans 
using the native rpm-1 promoter, which is expressed in neurons. An anti-GFP 
antibody was used to immunoprecipitate RPM-1::GFP from whole worm lysates, 
and RPM-1 binding proteins were identified using mass spectrometry and de 
novo peptide sequencing. Using this approach, we previously identified GLO-4 
and RAE-1 as functional RPM-1 binding proteins (Grill et al., 2007; Grill et al., 
2012). This proteomic screen also identified a phosphatase, PPM-2 (T23F11.1).  
 PPM-2 is in the Protein Phosphatase 2C (PP2C) family, which is also 
called the Protein Phosphatase Mg/Mn dependent (PPM) family. PP2C 
phosphatases are single subunit enzymes with serine/threonine phosphatase 
activity. Previous studies have shown that PPM-2 (also called PP2Cg2) has 
orthologs in yeast and Drosophila (Stern et al., 2007). We have found evidence 
of a PPM-2 ortholog in the genome sequence of the protochordate Ciona 
intestinalis (XP_002127931.1).  
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 Our proteomic analysis identified 5 unique peptides that covered 15% of 
the total PPM-2 protein sequence (data not shown). To confirm our proteomic 
result, we performed coimmunoprecipitation (coIP) from transgenic C. elegans. 
Animals were generated that expressed FLAG epitope tagged PPM-2 
(FLAG::PPM-2) and RPM-1::GFP specifically in neurons using a pan-neuronal 
promoter (Prgef-1) and the rpm-1 promoter, respectively. FLAG::PPM-2 was 
immunoprecipitated from whole worm lysates using an anti-FLAG antibody, and 
coprecipitating RPM-1::GFP was detected in immunoblots with an anti-GFP 
antibody (Figure 2-1A). This observation confirmed that PPM-2 is part of a 
neuronal protein complex that includes RPM-1. 
 
2.2.2 ppm-2 regulates axon termination in the mechanosensory neurons 
Our promoter expression studies showed that the ppm-2 promoter is active in 
many neurons including those of the nerve ring (Figure 2-1B), the motor neurons 
(Figure 2-1C), and the mechanosensory neurons (Figure 2-1D and E). ppm-2 
promoter activity was also detected in gut, muscle, and pharynx (data not 
shown). Because PPM-2 binds to RPM-1 and is expressed in a wide range of 
neurons, we hypothesized that PPM-2 might function in neuronal development, 
similar to RPM-1. To test this hypothesis, we analyzed two alleles of ppm-2, 
ok2186 and tm3480. As shown in Figure 2-2A, ok2186 is a deletion mutation that 
removes 1421 base pairs of sequence. ok2186 deletes 5' intronic sequence as 
well as exonic sequence. This suggests that ok2186 results in a truncated protein  
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at minimum and presumably causes a premature stop. Importantly, ok2186 
deletes three conserved residues (D59, H61 and R185, Figure 2-2B) that are 
required for the catalytic activity of PP2C phosphatases (Jackson et al., 2003; 
Takekawa et al., 1998). Thus, ok2186 is likely to be a molecular null allele. 
tm3480 is a deletion that removes 594 base pairs of ppm-2 sequence, generates 
a frame-shift, and results in nonsense sequence encoding 7 amino acids prior to 
premature termination of the open reading frame (Figure 2-2A). The premature 
stop in tm3480 leads to a predicted protein that is truncated and lacks two 
Figure 2-1. RPM-1 binds to the PP2C phosphatase PPM-2.  
(A) RPM-1::GFP was transgenically expressed in the neurons of C. elegans alone or in 
combination with FLAG::PPM-2. Coprecipitating RPM-1::GFP was detected with FLAG::PPM-
2 (upper panel). Levels of FLAG::PPM-2 (middle blot) and RPM-1::GFP (lower blot) were 
determined by immunoprecipitation (IP). (B and C) At left are epifluorescent images of 
transgenic animals expressing GFP from the native ppm-2 promoter (Pppm-2::GFP). At right 
are schematic diagrams of the cells, nerve cords or regions of interest. Pppm-2::GFP 
expression was detected in (B) the nerve ring, and in (C) the dorsal and ventral nerve cords. 
(D and E) Shown are epifluorescent images of transgenic animals expressing both GFP from 
the native ppm-2 promoter (Pppm-2::GFP) and mCherry from a cell-specific promoter for the 
mechanosensory neurons (Pmec-7::mCherry). Expression of Pppm-2::GFP detected in (D) 
an ALM mechanosensory neuron (arrow) and (E) a PLM mechanosensory neuron (arrow). In 
all cases, multiple independently derived transgenic lines showed similar results, and images 
from a representative transgenic line are shown. Scale bars are 10mm. 
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conserved residues (R185 and D228) that are required for catalytic activity 
(Figure 2-2B) (Jackson et al., 2003; Takekawa et al., 1998). Therefore, tm3480 is 
likely to be a molecular null allele. On gross examination, ppm-2-/- mutants had 
normal body size and shape, and moved normally. 
Previous studies in C. elegans have shown that rpm-1 regulates axon 
termination in the mechanosensory neurons (touch receptor neurons), which 
sense soft touch (Grill et al., 2007; Schaefer et al., 2000). These neurons are an 
excellent model to study axon termination for two reasons. First, C. elegans 
mechanosensory neurons terminate axon extension at precise anatomical 
locations (Chalfie and Thomson, 1979; Du and Chalfie, 2001), which are easily 
visualized using a transgene (muIs32) that expresses GFP in these cells (Ch'ng 
et al., 2003). Second, C. elegans and mammals share a similar but poorly 
understood mechanism that governs axon termination of sensory neurons. This 
is supported by the observation that loss-of-function mutations in C. elegans rpm-
1, Drosophila Highwire, and murine Phr1 result in axon termination defects in 
sensory neurons (Kim et al., 2013; Lewcock et al., 2007; Schaefer et al., 2000). 
C. elegans has two Posterior Lateral Microtubule (PLM) mechanosensory 
neurons. Each PLM neuron extends a single axon that terminates extension prior 
to the cell body of the Anterior Lateral Microtubule (ALM) mechanosensory 
neuron (Figure 2-2C, see schematic). In contrast, in rpm-1-/- animals the PLM 
axons fail to terminate extension properly, overgrow, and hook toward the ventral
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Figure 2-2. ppm-2 regulates axon termination of PLM neurons.  
(A) Schematic diagram of the ppm-2 open reading frame. Exons are shown with boxes and 
introns as lines. Deletions generated by ok2186 and tm3480 are shown below. (B) Schematic 
diagram of the PPM-2 protein. Conserved residues that are required for catalytic activity are 
highlighted. Protein sequence deleted by ok2186 and tm3480 are shown below. (C and D) 
Defects in axon termination of the PLM mechanosensory neurons were visualized using 
muIs32 (Pmec-7GFP). (C) Upper panel is a schematic diagram showing the mechanosensory 
neurons of C. elegans (modified from Worm Atlas). The box highlights the region shown below 
that was visualized using epifluorescent microscopy. An example of a PLM axon that 
overextends and hooks (hook) is shown for both ppm-2(ok2186)-/- and rpm-1-/- genotypes 
(arrowheads). Scale bar is 10 µm. (D) Quantitation of axon termination defects (hook 
represented in black, or overextension alone represented in grey) for the indicated genotypes. 
Averages are shown for data collected from 5-8 independent counts of 20-30 PLM neurons 
from young adult worms (16-20 hours post L4) grown at 23oC. Error bars represent the 
standard error of the mean, and significance was determined using an unpaired t-test. ** 
p<0.01, *** p<0.001 and ns = not significant. 
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side of the animal (Figure 2-2C). These overextension and hook defects, which 
will be referred to as “hook” defects for brevity of presentation, are highly 
penetrant in rpm-1-/- mutants (90.8 +/- 2.0% hook, Figure 2-2D). As noted in 
previous work, rpm-1-/- mutants also have a lower penetrance defect in which 
the PLM axon overextends, but does not hook (Figure 2-2D) (Grill et al., 2012; 
Tulgren et al., 2011). We refer to this phenotype simply as an “overextension” 
defect. ppm-2(ok2186)-/- and ppm-2(tm3480)-/- animals had hook defects that 
were of similar severity to rpm-1-/- mutants (Figure 2-2C), but the defects 
occurred with much lower penetrance (compare 9.0 +/- 2.2% for ppm-2(ok2186) 
and 9.3 +/- 2.2% for ppm-2(tm3480) to 90.8 +/- 2.0% for rpm-1, Figure 2-2D).  
ppm-2-/- mutants did not show significant overextension defects (Figure 2-2D).  
 In order to understand the genetic relationship between PPM-2 and other 
RPM-1 binding proteins, we made double mutants of ppm-2 with fsn-1 or glo-4. 
FSN-1 is an F-box protein that mediates the ubiquitin ligase activity of RPM-1 
(Grill et al., 2007; Liao et al., 2004), and GLO-4 is a putative guanine nucleotide 
exchange factor (GEF) that is positively regulated by RPM-1 (Grill et al., 2007). 
Previous studies established that fsn-1 and glo-4 function in parallel genetic 
pathways (Grill et al., 2007; Tulgren et al., 2011). However, both fsn-1 and glo-4 
function downstream of rpm-1, and in the same pathway as rpm-1 to regulate 
axon termination and synapse formation (Grill et al., 2007; Liao et al., 2004). 
Consistent with prior work, fsn-1-/- and glo-4-/- single mutants displayed hook 
defects, but these defects occurred with less penetrance than in rpm-1-/- animals 
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(compare 22.0 +/- 2.7% for glo-4 and 9.5 +/- 1.6% for fsn-1 to 90.8 +/- 2.0% for 
rpm-1, Figure 2-2D). In contrast, ppm-2-/- fsn-1-/- double mutants had strongly 
enhanced penetrance of hook defects (compare 89.4 +/- 2.0% for ppm-2(ok2186) 
fsn-1 and 94.0 +/- 1.5% for ppm-2(tm3480) fsn-1 to 9.5 +/- 1.6% for fsn-1, Figure 
2-2D). Hook defects were also mildly enhanced in ppm-2-/-; glo-4-/- double 
mutants (compare 41.8 +/- 2.8% for ppm-2(ok2186); glo-4 to 22.0 +/- 2.7% for 
glo-4, Figure 2-2D). 
Aside from defective axon termination in the PLM neurons, rpm-1-/- 
mutants also had other defects in the mechanosensory neurons, similar to what 
was described previously (Grill et al., 2007; Schaefer et al., 2000). In rpm-1-/- 
mutants, 85.6 +/- 1.6% of the PLM neurons that were analyzed lacked a synaptic 
branch (Figure 2-3). Notably, a previous study showed that the absence of the  
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PLM synaptic branch was due to a failure in synapse formation and/or maturation 
(Schaefer et al., 2000).  ppm-2-/- fsn-1-/- double mutants had enhanced 
penetrance of defects in synaptic branch extension (70.5 +/- 4.3% for ppm-
2(ok2186) fsn-1) compared to ppm-2-/- single mutants (6.6 +/- 1.3% for ppm-
2(ok2186)) or fsn-1-/- single mutants (3.5 +/- 1.2%) (Figure 2-3).  Thus, ppm-2-/- 
fsn-1-/- double mutants have enhanced defects in both axon termination and 
synaptogenesis in PLM neurons.  
In rpm-1-/- animals, 66.1 +/- 2.1% of the ALM neurons had axon 
termination defects in which the ALM axon overgrew and extended towards the 
posterior of the animal, which we refer to as big hooks (Figure 2-4). ppm-2-/- fsn-
1-/- double mutants had enhanced penetrance of defects in axon termination of 
the ALM neurons (37.6 +/- 4.1% big hook for ppm-2(ok2186) fsn-1) compared to 
either single mutant (0% for ppm-2(ok2186) and 12.5 +/- 2.0% for fsn-1, Figure 2-
4). 
While both alleles of ppm-2 are likely to be molecular null alleles, we 
wanted to confirm this experimentally. To do so, we generated ppm-
2(ok2186/tm3480) fsn-1-/- transheterozygous animals. The penetrance of hook  
Figure 2-3. ppm-2 regulates synaptogenesis, as assessed by synaptic branch 
extension, of the PLM neurons.  
The synaptic branch of the PLM neurons was visualized using the transgene muIs32 (Pmec-
7GFP). (A) Epifluorescent microscopy was used to visualize the synaptic branch in wild-type or 
rpm-1-/- mutant animals. The images shown correspond to the boxed region of the diagram. 
Note the absence of the synaptic branch in rpm-1-/- mutants (arrow). Scale bar is 10 µm. (B) 
Quantitation of the defects in synaptic branch extension in the PLM neurons for the indicated 
genotypes. Averages are shown for data collected from 5-8 independent counts of 20-30 PLM 
neurons from adult worms grown at 23°C. Error bars represent the standard error of the 
mean, and significance was determined using an unpaired t-test. *** p<0.001 and ns = not 
significant. 
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defects in the PLM neurons was enhanced in ppm-2(ok2186/tm3480) fsn-1-/- 
animals (82.8 +/- 2.0%) compared to fsn-1-/- single mutants (9.5 +/- 1.6%) and 
ppm-2-/- single mutants (9.0 +/- 2.2% for ppm-2(ok2186) and 9.3 +/- 2.2% for 
ppm-2(tm3480), Figure 2-2D). These results are consistent with the interpretation 
Figure 2-4. ppm-2 regulates axon termination of the ALM neurons.  
The axons of ALM mechanosensory neurons were visualized using the transgene muIs32 
(Pmec-7GFP). (A) Epifluorescent microscopy was used to visualize the ALM axon in wild-type or 
rpm-1-/- mutants. The images shown correspond to the boxed region of the diagram. Note that 
in rpm-1-/- mutants two types of axon termination defects are visible: 1) more severe big 
hooks in which the axon overextends and hooks to the posterior of animal (top panel), and 2) 
less severe short hooks in which the axon overextends more modestly, and does not extend 
towards the posterior (lower panel). (B) Quantitation of specific, short hook (grey) or big hook 
(black), axon termination defects in the ALM mechanosensory neurons of the indicated 
genotypes. Averages are shown for data collected from 5-8 independent counts of 20-30 ALM 
neurons from adult worms grown at 23°C. Error bars represent the standard error of the mean, 
and significance was determined using an unpaired t-test. *** p<0.001 and ns = not significant. 
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that both alleles of ppm-2 are genetic nulls. Thus, our observation that null alleles 
of ppm-2 enhance null alleles of glo-4 or fsn-1 is consistent with ppm-2 
functioning in a parallel genetic pathway to both glo-4 and fsn-1. 
 Previous students have shown that rpm-1-/- mutant phenotypes are 
partially suppressed by loss-of-function (lf) mutations in dlk-1, because DLK-1 is 
targeted for ubiquitination and degradation by RPM-1 (Grill et al., 2007; Nakata et 
al., 2005). Given that PPM-2 is an RPM-1 binding protein, it was possible that 
RPM-1 might ubiquitinate and degrade PPM-2. To test this possibility, we 
constructed ppm-2-/-; rpm-1-/- double mutants. The PLM and ALM axon 
termination defects (Figure 2-2B and 2-4), and the defects in synaptic branch 
extension of the PLM neurons (Figure 2-3) were similar between ppm-2-/-; rpm-
1-/- double mutants and rpm-1-/- single mutants. These observations suggest 
that PPM-2 is not targeted for ubiquitination and degradation by RPM-1. These 
results are also consistent with ppm-2 functioning in the same genetic pathway 
as rpm-1. 
 It should be noted that although rpm-1-/- mutants have defects in axon 
termination and synapse formation in the mechanosensory neurons, previous 
studies have shown that rpm-1-/- mutants have normal locomotion, have normal 
soft touch sensation and are mildly dumpy (Schaefer et al., 2000; Zhen et al., 
2000). We observed that ppm-2-/- mutants had normal body size, normal 
locomotion, and sensed soft touch normally (data not shown). Thus, defects in 
  43 
axon termination associated with loss of function in the RPM-1 pathway do not 
lead to changes in the ability of the mechanosensory neurons to sense touch. 
 
2.2.3 ppm-2 functions cell autonomously, downstream of rpm-1 to regulate 
axon termination 
Having established that ppm-2 regulates axon termination in the 
mechanosensory neurons, we next sought to determine if the genetic lesion in 
ppm-2(ok2186) was responsible for the observed axon termination defects. 
Given that RPM-1 and its known binding proteins function cell autonomously in 
the mechanosensory neurons (Grill et al., 2007; Grill et al., 2012; Schaefer et al., 
2000), we also wanted to determine if PPM-2 functions cell autonomously. Using 
a transgenic approach, ppm-2-/- fsn-1-/- double mutants were engineered with an 
extrachromosomal array expressing PPM-2. We opted to analyze transgenic 
rescue using ppm-2-/- fsn-1-/- double mutants because axon termination defects 
were more penetrant in these animals than ppm-2-/- single mutants, thus 
facilitating ease of analysis. When PPM-2 was expressed in the mechanosensory 
neurons using a cell specific promoter (Pmec-7), the axon termination defects in 
ppm-2-/- fsn-1-/- double mutants were significantly rescued (compare 89.4 +/- 
2.0% for ppm-2 fsn-1 with 32.0 +/- 2.5% for ppm-2 fsn-1 + Pmec-7::PPM-2, 
Figure 2-5A). In contrast, PPM-2 that was point mutated at a conserved residue 
(D59N) that is required for PP2C phosphatase activity, did not rescue the defects 
in ppm-2-/- fsn-1-/- double mutants (Figure 2-5A). These observations are  
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Figure 2-5. ppm-2 functions cell autonomously downstream of rpm-1.  
The PLM axon termination defects (hook) were quantified for all genotypes shown using the 
transgene muIs32. (A) A cell specific promoter (Pmec-7) was used to transgenically express 
wild-type PPM-2, phosphatase-dead PPM-2 D59N, or PPM-2 G2A that was not N-
myristoylated in the PLM neurons of ppm-2-/- fsn-1-/- double mutants. (B) A cell specific 
promoter (Pmec-7) was used to transgenically express PPM-2 or phosphatase-dead PPM-2 
D59N in rpm-1-/- single mutants. Averages are shown for data collected from 5 or more 
transgenic lines for each genotype. In all experiments, young adult worms (16-20 hours post 
L4) grown at 23oC were analyzed. Error bars represent the standard error of the mean, and 
significance was determined using an unpaired t-test.  *** p<0.001 and ns = not significant 
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consistent with ppm-2 functioning cell autonomously through its phosphatase 
activity to regulate axon termination in the mechanosensory neurons.  
Our genetic analysis showed that ppm-2 functions in the same pathway as 
rpm-1, and we wanted to test if ppm-2 functions up or downstream of rpm-1. To 
do so, we generated rpm-1-/- mutants that carried a transgenic 
extrachromosomal array that expressed PPM-2 specifically in the 
mechanosensory neurons. We observed that overexpression of PPM-2 partially 
rescued the axon termination defects in rpm-1-/- mutants (compare 90.8 +/- 2.0 
% for rpm-1 to 28.8 +/- 9.2% for rpm-1 + Pmec-7::PPM-2, Figure 2-5B). Defects 
were not rescued by overexpression of PPM-2 D59N (Figure 2-5B). These 
observations are consistent with ppm-2 functioning downstream of rpm-1.  
 
 
2.2.4 N-myristoylation is required for PPM-2 to be fully functional 
During our mass spectrometry analysis, we detected N-myristoylation of a PPM-2 
peptide (data not shown). Sequence analysis confirmed that the N-myristoylated 
glycine in PPM-2 is highly conserved with other PP2C family phosphatases (data 
not shown). To test if N-myristoylation was important for the function of PPM-2, 
we generated a point mutant of PPM-2, G2A, that cannot be myristoylated. We 
found that transgenic expression of PPM-2 G2A moderately rescued the axon 
termination defects in ppm-2-/- fsn-1-/- animals compared to wild-type PPM-2 
(compare 89.4 +/- 2.0% for ppm-2 fsn-1 to 32.0 +/- 2.5% for ppm-2 fsn-1 + Pmec-
7::PPM-2 and 62.2 +/- 4.8% for ppm-2 fsn-1 + Pmec-7::PPM-2 G2A, Figure 2-
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5A). This observation demonstrates that N-myristoylation is required for PPM-2 
to function with full efficacy. 
 
2.2.5 PPM-2 negatively regulates DLK-1 
Previous studies in yeast, Arabidopsis, C. elegans, Drosophila, and cultured 
mammalian cells have shown that PP2C phosphatases can negatively regulate 
MAPK or MAP3K signaling (Baril et al., 2009; Hanada et al., 2001; Meskiene et 
al., 1998; Nguyen and Shiozaki, 1999; Takekawa et al., 1998; Tulgren et al., 
2011). Given that RPM-1 negatively regulates a MAPK pathway that includes 
DLK-1, MKK-4 and PMK-3, we hypothesized that PPM-2 might also negatively 
regulate one or more of the kinases in this pathway. We began our analysis by 
studying the most upstream kinase in the pathway, the MAP3K DLK-1. 
Consistent with the interpretation that PPM-2 negatively regulates DLK-1, axon 
termination defects in the PLM neurons were suppressed in ppm-2-/-; dlk-1-/- 
double mutants (0% defect) compared to ppm-2-/- single mutants (9.0 +/- 2.2%, 
Figure 2-6A). Because PLM axon termination defects occur in ppm-2-/- mutants 
with low penetrance, we also performed our suppressor analysis using glo-4-/-; 
ppm-2-/- double mutants. Consistent with a previous study (Grill et al., 2007), we 
found that the hook defects in glo-4-/- single mutants were not suppressed by 
dlk-1 (lf) (Figure 2-6A). In contrast, the enhanced penetrance of hook defects 
seen in glo-4-/-; ppm-2-/- double mutants (41.8 +/- 2.8%) was suppressed in glo-
4-/-; ppm-2-/-; dlk-1-/- triple mutants (20.5 +/- 2.6%, Figure 2-6A). 
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Figure 2-6. PPM-2 negatively regulates the MAP3K DLK-1.  
PLM axon termination defects (hook) were quantified for the indicated genotypes using the 
transgene muIs32. (A) Loss of function in dlk-1 suppresses the axon termination defects in 
ppm-2-/- single mutants and glo-4-/-; ppm-2-/- double mutants. Shown are averages for data 
collected from 5-8 independent counts of 20-30 PLM neurons from young adult worms (16-20 
hours post L4) grown at 23oC for each genotype. (B) Transgenic overexpression of the 
MAP3K DLK-1, or the MAP2K MKK-4 results in PLM axon termination defects (hook). 
Coexpression of PPM-2 rescues defects caused by overexpression of DLK-1, but not MKK-4. 
Shown are averages for data pooled from 5 or more transgenic lines for the indicated 
genotypes; young adult worms grown at 23oC were analyzed.  For A and B, error bars 
represent the standard error of the mean, and significance was determined using an unpaired 
t-test. ** p< 0.005, *** p<0.001 and ns = not significant 
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Previous studies in flies have shown that DLK/Wallenda functions 
downstream of DFsn (Wu et al., 2007). Consistent with these findings, we found 
that fsn-1-/-; dlk-1-/- double mutants were fully suppressed for hook defects 
compared to fsn-1-/- single mutants (compare 9.5 +/- 1.6% for fsn-1 to 0% for 
fsn-1; dlk-1, Figure 2-6A). We also observed that enhanced hook defects in fsn-
1-/- ppm-2-/- double mutants were fully suppressed in fsn-1-/- ppm-2-/-; dlk-1-/- 
triple mutants (compare 89.4 +/- 2.0% for fsn-1 ppm-2 to 1.69 +/- 0.8% for fsn-1 
ppm-2; dlk-1, Figure 2-6A). These results suggest that ppm-2 and fsn-1 function 
in a parallel genetic pathway that converges on the common target of dlk-1.   
 Having shown that PPM-2 negatively regulates the DLK-1 pathway, we 
next wanted to test if a specific kinase(s) in the pathway was regulated by PPM-
2. To do so, we generated transgenic animals with extrachromosomal arrays that 
expressed a kinase in the DLK-1 pathway alone, or in combination with PPM-2. 
Similar to our previous observations (Tulgren et al., 2011), transgenic 
overexpression of DLK-1 or its downstream kinase MKK-4 using a pan-neuronal 
promoter (Prgef-1) resulted in axon termination defects in the PLM neurons (64.3 
+/- 10.4% for Prgef-1::DLK-1 and 34.7 +/- 2.5% for Prgef-1::MKK-4, Figure 2-6B). 
Notably, MKK-4 overexpression did not cause as penetrant a phenotype as DLK-
1 overexpression, presumably because the activity of MKK-4 is limited by the 
amount of endogenous upstream DLK-1 kinase activity. Coexpression of PPM-2 
significantly rescued the defects caused by overexpression of DLK-1, but not the 
defects caused by overexpression of MKK-4 (compare 64.3 +/- 10.4% for Prgef-
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1::DLK-1 to 19.2 +/- 2.0% for Prgef-1::DLK-1 + Pmec-7::PPM-2, Figure 2-6B). It 
should be noted that we expressed DLK-1 and MKK-4 at moderate levels 
(2.5ng/µL PCR product injected for DLK-1 and 5ng/µL for MKK-4) in order to 
maximize the potential for rescue by coexpression of PPM-2. Importantly, 
incorporation of a second transgene into arrays did not rescue defects caused by 
DLK-1 overexpression, as inactive PPM-2 D59N did not show rescue (Figure 2-
6B). Thus, PPM-2 acts through its phosphatase activity to negatively regulate 
DLK-1, but not MKK-4. Because PMK-3 functions downstream of MKK-4 (Nakata 
et al., 2005), our results are also consistent with the conclusion that PPM-2 does 
not regulate PMK-3. Overall, our results indicate that PPM-2 negatively regulates 
an upstream activator of DLK-1, acts on an inhibitor of DLK-1, or negatively 
regulates DLK-1 directly.  
 
2.2.6 PPM-2 acts on DLK-1 
Our genetic and transgenic experiments indicated that PPM-2 might directly 
dephosphorylate DLK-1. To test this hypothesis, we first determined if PPM-2 
bound to DLK-1. To do so, we engineered transgenic C. elegans that used a 
pan-neuronal promoter (Prgef-1) to coexpress a GFP fusion protein of PPM-2 
(PPM-2::GFP) with FLAG epitope tagged DLK-1 (FLAG::DLK-1). Because wild-
type DLK-1 could not be expressed at sufficient levels for biochemistry (data not 
shown), we used a point mutant of DLK-1 K162R that has reduced kinase activity 
and can be expressed at higher levels to facilitate our analysis (Abrams et al., 
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2008). Both wild-type PPM-2 and catalytically inactive PPM-2 D59N 
coprecipitated with DLK-1 (Figure 2-7A). Thus, PPM-2 is physically associated 
with DLK-1 or a protein complex that contains DLK-1.  
A previous study identified a conserved point mutation in mammalian 
PP2Ca that results in increased binding to direct targets of dephosphorylation 
(Takekawa et al., 1998). This phosphatase trapping strategy has been used with 
other types of phosphatases as well (Furukawa et al., 1994; Sun et al., 1993). 
We observed that the corresponding point mutation in PPM-2, R185A, results in 
increased binding to DLK-1 K162R (Figure 2-7B). Quantitation of this interaction 
using multiple, independently-derived transgenic lines showed that PPM-2 
R185A has significantly increased binding to DLK-1 (1.5 +/- 0.2), when compared 
to the level of binding between wild-type PPM-2 and DLK-1 (0.4 +/- 0.1, Figure 2-
7C).  
 To further reinforce our model that DLK-1 is directly targeted for 
dephosphorylation by PPM-2, we used a combination of transgenics and 
biochemistry. During generation of animals with transgenic extrachromosomal 
arrays that used a pan-neuronal driver (Prgef-1) to express wild-type PPM-
2::GFP or catalytically inactive PPM-2::GFP D59N, we noticed that the 
expression of PPM-2 D59N was elevated compared to wild-type PPM-2 (Figure 
2-7D). This suggested that in neurons excess PPM-2 phosphatase activity is 
problematic, presumably due to dephosphorylation of endogenous targets. Thus, 
transgenic coexpression of PPM-2 with one of its direct dephosphorylation  
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targets should result in elevated expression of PPM-2 due to titration of 
phosphatase activity. Consistent with this hypothesis, levels of wild-type PPM-
2::GFP were increased when DLK-1 K162R was transgenically coexpressed, 
Figure 2-7. PPM-2 binds to DLK-1.  
CoIP from transgenic whole worm lysates showing that (A) PPM-2::GFP and PPM-2::GFP 
D59N bind to FLAG::DLK-1 K162R (upper panel) (B) PPM-2::GFP R185A shows increased 
binding to FLAG::DLK-1 K162R compared to wild-type PPM-2::GFP (upper panel). (C) 
Quantitation of PPM-2::GFP coIP with FLAG::DLK-1 K162R. Note that data was acquired from 
2 independently derived transgenic lines for each genotype, and histograms represent the 
ratio of the amount of PPM-2::GFP or PPM-2::GFP R185A in coIP to the amount of 
FLAG::DLK-1 K162R that was immunoprecipitated. (D) Immunoblots of whole worm lysates 
generated solely from transgenic worms. Catalytically inactive PPM-2::GFP D59N was 
consistently expressed at elevated levels compared to wild-type PPM-2::GFP (upper panel). 
(E) Immunoblots of whole worm lysates generated solely from transgenic worms. The level of 
wild-type PPM-2::GFP was elevated when coexpressed with FLAG::DLK-1 K162R, compared 
to when it was coexpressed with mCherry (upper panel). (F) Quantitation of PPM-2::GFP 
levels from lysates of the indicated transgenic genotypes. Shown are the average levels of 
PPM-2 acquired from 4 independently derived transgenic lines for each genotype normalized 
to MPK-1 (loading control). Error bars represent the standard error of the mean, and 
significance was determined using an unpaired t-test. ** p< 0.01, *** p<0.001, ns = not 
significant. 
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compared to when PPM-2::GFP was coexpressed with a control protein, 
mCherry (Figure 2-7E). Because whole worm lysates used for these experiments 
were generated exclusively from transgenic animals, it was possible to use 
endogenous MPK-1 (the C. elegans Erk1 MAPK) as a loading control. As shown 
in Figure 2-7E, the levels of MPK-1 were similar between different transgenic 
samples. Quantitation of PPM-2::GFP levels using multiple, independently 
derived transgenic lines showed that coexpression of PPM-2::GFP with 
FLAG::DLK-1 K162R resulted in a significant increase in PPM-2::GFP expression 
levels (2.5 +/- 0.5) compared to coexpression with mCherry (0.3 +/- 0.1, Figure 2-
7F). Collectively, these results support the conclusion that DLK-1 is likely to be a 
direct target of PPM-2 phosphatase activity.  
 
2.2.7 PPM-2 acts on serine 874 in DLK-1L 
A recent study showed that two conserved serine residues, S874 and S878, in 
the C-terminus of the long/full-length isoform of DLK-1 (DLK-1L) regulate its 
activity (Yan and Jin, 2012). When DLK-1L is phosphorylated, it homodimerizes 
and is active. When DLK-1L is dephosphorylated, it preferentially binds to a short 
isoform of DLK-1 (called DLK-1S) creating an inactive heterodimer. Given our 
observation that PPM-2 is a serine/threonine phosphatase that negatively 
regulates DLK-1, we tested if PPM-2 functions by dephosphorylating one or both 
of these C-terminal serine residues in DLK-1L. To test this hypothesis, we used a 
transgenic approach and analyzed axon termination in the PLM neuron. We 
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generated transgenic animals with extrachromosomal arrays that expressed 
either wild-type DLK-1L or a phosphomimetic point mutant of DLK-1L (S874E 
S878E) alone or in combination with PPM-2. Transgenic overexpression of DLK-
1 or DLK-1 S874E S878E using a pan-neuronal promoter (Prgef-1) resulted in 
similar penetrance of hook defects in the PLM neurons (55.5 +/- 4.2% for DLK-1 
and 56.8 +/- 5.4% for DLK-1 S874E S878E, Figure 2-8A). Coexpression of PPM-
2 significantly rescued the defects caused by overexpression of DLK-1 (compare 
55.5 +/- 4.2% for DLK-1 and 22.6 +/- 5.6% for DLK-1 + PPM-2), but did not 
rescue defects caused by overexpression of DLK-1 S874E S878E (compare 56.8 
+/- 5.4% for DLK-1 S874E S878E and 46.1 +/- 2.3% for DLK-1 S874E S878E + 
PPM-2, Figure 2-8A). These results suggest that PPM-2 regulates 
phosphorylation of DLK-1L at S874, S878 or both serine residues.  
We further mapped the target residue in DLK-1L that was regulated by 
PPM-2 by testing DLK-1L that was solely mutated at S874 or S878. As shown in 
Figure 2-8A, transgenic overexpression of DLK-1 S874E or DLK-1 S878E 
resulted in axon termination defects in the PLM neurons (59.1 +/- 6.8% for DLK-1 
S874E and 56.1 +/- 7.2% for DLK-1 S878E). Coexpression of PPM-2 significantly 
rescued the defects caused by overexpression of DLK-1 S878E (compare 56.1 
+/- 7.2% for DLK-1 S878E and 17.0 +/- 3.0% for DLK-1 S878E + PPM-2, Figure 
2-8A). In contrast, PPM-2 did not rescue defects caused by overexpression of  
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Figure 2-8. PPM-2 regulates DLK-1 by acting on S874.  
(A) Quantitation of PLM axon termination defects (hook) caused by transgenic overexpression 
of DLK-1 and phosphomimetic DLK-1 point mutants. Note that coexpression of PPM-2 
rescues defects caused by overexpression of DLK-1, but not defects caused by 
overexpression of DLK-1 S874E S878E and DLK-1 S874E. Shown are averages of data 
pooled from 5 or more transgenic lines for the indicated genotypes; young adult worms (16-20 
hours post L4) grown at 23oC were analyzed. (B) CoIP from transgenic whole worm lysates 
showing that FLAG::DLK-1L K162R coprecipitates with GFP::DLK-1S, and binding of DLK-1L 
to DLK-1S is not altered in ppm-2-/- mutants (upper panel). (C) Quantitation of FLAG::DLK-1L 
K162R coIP with GFP::DLK-1S for the indicated genotypes normalized to amount of 
GFP::DLK-1S precipitated. Shown are the average levels of FLAG::DLK-1 K162R 
coprecipitating with GFP::DLK-1S acquired from 3 independently derived transgenic lines for 
each genotype. Error bars represent the standard error of the mean, and significance was 
determined using an unpaired t-test.  ** p< 0.01, *** p<0.001, ns = not significant. 
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DLK-1 S874E (Figure 2-8A). Thus, PPM-2 regulates the activity of DLK-1L by 
acting on S874. 
 Given the results of our functional transgenic experiments, we next 
wanted to test if PPM-2 regulated the binding of DLK-1L to DLK-1S. We 
generated transgenic worms that used the pan-neuronal rgef-1 promoter to 
coexpress FLAG::DLK-1L K162R with GFP::DLK-1S. As shown in Figure 2-8B, 
DLK-1L coprecipitates with DLK-1S, which is consistent with previous 
observations made using yeast two-hybrid analysis and a heterologous 
expression system (Yan and Jin, 2012). The interaction between DLK-1L and 
DLK-1S was unchanged in ppm-2-/- mutants (Figure 2-8B and C). 
 Thus, our functional genetic and biochemical experiments demonstrate 
that PPM-2 acts at S874 to regulate phosphorylation and activation of DLK-1. 
Our results are consistent with two possible signaling models: 1) S874 is an 
activating phosphorylation site on DLK-1L that is regulated by PPM-2, and does 
not regulate binding to DLK-1S. 2) DLK-1L must be phosphorylated at both S874 
and S878 to prevent binding of DLK-1S and allow DLK-1L activation.  
 
2.2.8 ppm-2 regulates synapse formation by GABAergic motor neurons 
Previous studies in C. elegans have shown that rpm-1 regulates synapse 
formation in motor neurons (Nakata et al., 2005; Zhen et al., 2000). In C. 
elegans, there are two sets of GABAergic, inhibitory motor neurons: the VD 
neurons that innervate the ventral muscles, and the DD neurons that innervate 
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the dorsal muscles (Figure 2-9A, see schematic). The presynaptic terminals of 
VD and DD motor neurons were visualized in living worms using juIs1, a 
transgene that uses a cell-specific promoter (Punc-25) to drive expression of a 
fusion protein of Synaptobrevin 1 (SNB-1) and GFP (SNB-1::GFP) (Hallam and 
Jin, 1998). In wild-type animals, SNB-1::GFP localized to presynaptic puncta that 
were uniform in size and evenly spaced along the dorsal nerve cord (Figure 2-
9A). In rpm-1-/- mutants, the dorsal SNB-1::GFP puncta were abnormal in size 
and aggregated (Figure 2-9A, arrowheads), and there were sections of the dorsal 
cord with gaps in which no SNB-1::GFP puncta were present (Figure 2-9A, 
arrows). Previous studies using electron microscopy established that defects in 
the localization of SNB-1::GFP in rpm-1-/- mutants reflect defects in synapse 
formation, rather than simply defects in the formation of presynaptic terminals or 
the trafficking of synaptic vesicles (Nakata et al., 2005; Zhen et al., 2000). 
Quantitation of the number of SNB-1::GFP puncta showed that rpm-1-/- animals 
had fewer synapses than wild-type animals (compare 11.3 +/- 0.4 SNB-1::GFP 
puncta/100mm for rpm-1 to 21.9 +/- 0.4 puncta/100mm for wild type, Figure 2-
9B). This observation was consistent with previous studies (Nakata et al., 2005; 
Tulgren et al., 2011).  
 To test if ppm-2 functions in synapse formation, we analyzed ppm-2-/- 
animals and a series of double mutants of ppm-2 and members of the RPM-1 
pathway. We found that ppm-2(ok2186)-/- and ppm-2(tm3480)-/- mutants had 
normal patterning and numbers of SNB-1::GFP puncta (Figure 2-9A and B). In 
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Figure 2-9. ppm-2 regulates synapse formation by GABAergic motor neurons.  
(A) Upper panel is a schematic diagram modified from Worm Atlas showing the GABAergic 
DD neurons that innervate the dorsal muscles (DD cell body and axon on the ventral side of 
the animal, and presynaptic terminals on the dorsal side of the animal). A transgene, juIs1 
(Punc-25SNB-1::GFP), and epifluorescent microscopy was used to visualize the presynaptic 
terminals of the DD motor neurons for the indicated genotypes. Arrows note regions of the 
dorsal cord where presynaptic terminals are absent. Arrowheads highlight abnormal 
aggregation of presynaptic terminals. Scale bar is 10 µm. (B) Quantitation of synapse 
formation defects. Shown are averages for data collected from 3 or more independent 
experiments performed at 25oC in which 15-20 synchronized, young adult worms (16-20 hours 
post L4) were analyzed. Error bars represent the standard error of the mean, and significance 
was determined using an unpaired t-test. * p<0.05, *** p<0.001 and ns = not significant. 
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contrast, ppm-2-/- fsn-1-/- and ppm-2-/-; glo-4-/- double mutants had enhanced 
defects in synapse formation (Figure 2-9A) compared to single mutants (compare 
14.2 +/- 0.5 puncta/100mm for ppm-2(tm3480) fsn-1 and 12.4 +/-1.7 for ppm-
2(ok2186) fsn-1 to 17.9 +/- 0.4 for fsn-1, Figure 2-9B). We also analyzed ppm-2-
/-; rpm-1-/- double mutants and found that they had similar defects in synapse 
formation to rpm-1-/- single mutants assessed qualitatively (Figure 2-9A) and 
quantitatively (Figure 2-9B). Our observations are consistent with two 
conclusions. First, ppm-2 functions in a parallel genetic pathway to both fsn-1 
and glo-4 to regulate synapse formation, since all the mutants used in our study 
are null alleles. Second, ppm-2 functions in the same genetic pathway as rpm-1 
to regulate synapse formation, as synapse formation defects in ppm-2-/-; rpm-1-/- 
double mutants were not enhanced, and the synapse formation defects in rpm-1-
/- mutants are not saturated (Liao et al., 2004). 
 
2.2.9 PPM-2 is localized to presynaptic terminals 
Having established the molecular mechanism of how PPM-2 functions in 
neuronal development, we wanted to determine if PPM-2 is localized to a 
particular subcellular compartment in neurons. To do so, we took a transgenic 
approach in which PPM-2 was expressed in the GABAergic motor neurons. The 
GABAergic motor neurons were analyzed to maintain consistency with prior cell 
biology studies on RPM-1 and its binding partners. A cell specific promoter 
(Punc-25) was used to express PPM-2 as a C-terminal fusion protein with GFP 
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(PPM-2::GFP), in order to ensure that GFP did not interfere with the 
myristoylation of PPM-2. PPM-2::GFP was localized broadly throughout the 
motor neuron axons and cell bodies with strong enrichment in puncta along the 
ventral and the dorsal nerve cord (Figure 2-10A). This localization pattern was 
similar to molecules that are localized to the presynaptic terminal, such as SNB-
1. To test this possibility, transgenic animals were generated that expressed a 
fusion protein of SNB-1 and dsRED (SNB-1::dsRED) with PPM-2::GFP in the 
GABAergic motor neurons. As shown in Figure 2-10B, PPM-2::GFP and SNB-
1::dsRED colocalized in puncta at the presynaptic terminals of the DD neurons 
on the dorsal side of the animal. Localization of PPM-2 to the presynaptic 
terminal is consistent with our finding that PPM-2 regulates synapse formation in 
the GABAergic motor neurons.  
Figure 2-10. PPM-2 localizes to the presynaptic terminal.  
(A) PPM-2::GFP was transgenically expressed in the GABAergic motor neurons using a cell 
specific promoter (Punc-25). Epifluorescent microscopy was used to visualize PPM-2::GFP 
puncta in the dorsal and ventral cords. (B) Transgenic worms expressing PPM-2::GFP and 
SNB-1::dsRED in the GABAergic motor neurons were analyzed by confocal microscopy. 
Shown are the presynaptic terminals of the DD neurons on the dorsal side of the animal. 
Scale bar is 10 µm. 
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2.3 Discussion 
How axon outgrowth, synapse formation, and termination of axon outgrowth are 
molecularly coordinated during development remains poorly understood. The 
PHR proteins meet a growing list of criteria as molecules that integrate and 
coordinate these events during development. The PHR proteins function in 
synapse formation (Burgess et al., 2004; Schaefer et al., 2000; Wan et al., 2000; 
Zhen et al., 2000), axon guidance and outgrowth (D'Souza et al., 2005; Lewcock 
et al., 2007; Li et al., 2008), and axon termination (Kim et al., 2013; Lewcock et 
al., 2007; Schaefer et al., 2000), and importantly often do so in the same type of 
neuron. Studies using C. elegans and Drosophila have shown that PHR proteins 
are extremely large, intracellular signaling proteins that function cell 
autonomously. Thus, PHR proteins have the potential to integrate signals coming 
from different extracellular cues converging on a single neuron. There is 
evidence suggesting that the activity of the PHR proteins can be regulated 
(Pierre et al., 2004; Tian et al., 2011), although the extracellular signals that 
activate or inhibit PHR proteins remain unclear. Finally, the PHR proteins 
negatively and positively regulate multiple downstream signaling pathways that 
control gene transcription (Collins et al., 2006; Guo et al., 1998; Lewcock et al., 
2007; Murthy et al., 2004; Nakata et al., 2005), signal transduction and local 
mRNA translation (Grill et al., 2007; Murthy et al., 2004; Pierre et al., 2008; 
Scholich et al., 2001; Yan et al., 2009), microtubule dynamics (Grill et al., 2012; 
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Hendricks and Jesuthasan, 2009; Lewcock et al., 2007), and vesicle 
trafficking/formation (Grill et al., 2007).  
 Studies in worms, flies, fish, and mice have shown that PHR proteins 
function as ubiquitin ligases to negatively regulate the MAP3K DLK, which 
represents a mechanism to control long-term signaling by the DLK pathway. We 
now show that C. elegans RPM-1 also utilizes a phosphatase, PPM-2, to 
negatively regulate DLK-1 (Figure 2-11). This suggests that RPM-1 has the 
potential to rapidly regulate signaling by DLK-1. Thus, our results suggest that 
RPM-1 has the potential to employ different regulatory mechanisms to spatially 
and/or temporally regulate DLK-1 signaling, which provides further support for 
the proposition that PHR proteins may coordinate different events during 
development. To our knowledge, RPM-1 also now represents the first example of 
Figure 2-11. Summary of RPM-1 signaling.  
RPM-1 is a positive regulator of the GLO-4 pathway, and acts as part of a complex with FSN-1 
that ubiquitinates and negatively regulates DLK-1. PPM-2 is also part of an RPM-1 protein 
complex and negatively regulates DLK-1 via dephosphorylation at S874.  
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a single signaling protein that controls both ubiquitination and dephosphorylation 
of a MAP3K.  
 
2.3.1 PPM-2 mediates RPM-1 function 
Our proteomic screen for RPM-1 binding proteins identified the PP2C 
phosphatase PPM-2, which we confirmed using coIP from transgenic C. elegans. 
Genetic and transgenic experiments showed that ppm-2 functions downstream of 
rpm-1 to regulate axon termination and synapse formation. Importantly, our 
genetic analysis also demonstrated that ppm-2 and rpm-1 function in the same 
genetic pathway consistent with our observation that these molecules physically 
interact.  
 Axon termination and synapse formation defects were enhanced in ppm-
2-/- fsn-1-/- double mutants and ppm-2-/-;glo-4-/- double mutants. Given that we 
analyzed null alleles of ppm-2, glo-4, and fsn-1, our results are consistent with 
these three molecules acting in parallel pathways that converge on a common 
molecular player or process in neurons. In the case of PPM-2 and FSN-1, we 
have identified this common player as DLK-1. It remains unclear which 
downstream molecule or process is commonly regulated by GLO-4 and PPM-2.  
 Our results support the conclusion that RPM-1 positively regulates PPM-2 
for several reasons. First, rpm-1 and ppm-2 (lf) mutants both have axon 
termination defects. Second, defects in ppm-2-/-; rpm-1-/- double mutants were 
not suppressed. If PPM-2 were negatively regulated by RPM-1, we would expect 
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that loss of function in ppm-2 would suppress the defects in rpm-1 mutants. Such 
is the case for DLK-1, which is negatively regulated by RPM-1 (Nakata et al., 
2005). Finally, none of the molecules we have identified in our proteomic screen 
for RPM-1 binding proteins (including: GLO-4, FSN-1, and RAE-1) have been 
genetic suppressors of rpm-1 (lf) (Grill et al., 2007; Grill et al., 2012). Thus, our 
screen does not efficiently identify ubiquitination targets of RPM-1, presumably 
because such interactions are transient. Overall, our data are consistent with the 
conclusion that RPM-1 binds to and positively regulates PPM-2. Nonetheless, 
developing a more refined mechanistic understanding of how PPM-2 is regulated 
by RPM-1 remains an important goal.  
 RPM-1 is highly conserved with functional orthologs in Drosophila, 
zebrafish, and mice. The RPM-1 binding proteins we previously identified in our 
proteomic screen, including GLO-4, FSN-1 and RAE-1, are also evolutionarily 
conserved from worms to mammals (Grill et al., 2007; Grill et al., 2012). With 
regard to PPM-2, we identified clear orthologs in Drosophila and the 
protochordate Ciona intestinalis, which suggests that PPM-2 is likely to represent 
a conserved mechanism by which PHR proteins function. However, due to lack 
of sequence conservation we were unable to identify an orthologous 
phosphatase to PPM-2 in vertebrates. While PPM-2 may represent a unique 
mechanism of regulating neuronal development in invertebrates and 
protochordates, it is also possible that another PP2C phosphatase (or a member 
of a different phosphatase family) may perform the function of PPM-2 in 
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vertebrate neurons. It is notable that the PP2C phosphatase PPM-1, which is one 
of the closest homologs of PPM-2 in C. elegans, also regulates axon termination 
and synapse formation (Tulgren et al., 2011). In mammals, PPM-1 has three 
orthologs, PP2Ca, PP2Cb, and PP2Cb-like. Because the PPM-1 subfamily has 
undergone significant expansion in mammals, PP2Ca, PP2Cb, and PP2Cb-like 
are plausible candidates as the functional ortholog of PPM-2. Future experiments 
in C. elegans using mammalian PP2C phosphatases may be helpful in 
addressing this possibility. 
 
2.3.2 A complex negative regulatory network controls the DLK-1 pathway 
RPM-1 and the PHR proteins function in part by ubiquitinating and negatively 
regulating the MAP3K DLK-1 (Collins et al., 2006; Lewcock et al., 2007; Nakata 
et al., 2005). Transgenic overexpression of DLK-1 at higher levels than used in 
our study causes more severe defects than rpm-1 (lf), such as uncoordinated 
locomotion and small body size (Abrams et al., 2008; Nakata et al., 2005). This 
observation suggested that negative regulatory mechanisms, aside from 
ubiquitination by RPM-1, restrain the activity of DLK-1 and/or its downstream 
kinases. Recent work in C. elegans has supported this hypothesis by showing 
that PPM-1 (a homolog of PPM-2) and VHP-1 (a dual specificity phosphatase) 
negatively regulate the DLK-1 pathway (Nix et al., 2011; Tulgren et al., 2011). 
Nonetheless, it remained uncertain if a specific phosphatase directly regulated 
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DLK-1. It also remained unclear if RPM-1 functions through mechanisms other 
than ubiquitination to control the activity of DLK-1.  
 We now address both these questions by showing that RPM-1 binds to 
the phosphatase PPM-2, and functions through this phosphatase-based 
mechanism to negatively regulate DLK-1 (Figure 2-11). Our biochemical and 
functional genetic analysis indicate that DLK-1 is negatively regulated by PPM-2. 
This is most likely the result of direct dephosphorylation as corroborated by 
several observations: 1) PPM-2 binds to DLK-1. 2) PPM-2 R185A acts as a trap 
for phosphorylation targets, and shows increased binding to DLK-1. 3) 
Transgenic expression of DLK-1 allows increased coexpression of PPM-2, 
presumably by titrating excess PPM-2 phosphatase activity that is otherwise 
problematic for neurons.  
 A previous study showed that phosphomimetic point mutation of DLK-1L 
at both S874 and S878 allowed DLK-1L to homodimerize and become active 
(Yan and Jin, 2012). Point mutations in DLK-1L that prevented phosphorylation 
at both S874 and S878 resulted in formation of an inactive heterodimer with DLK-
1S (short, inhibitory isoform). This prior study did not determine if 
phosphorylation of DLK-1L at S874, S878 or both residues was required to 
regulate binding to DLK-1S. We have found that PPM-2 acts specifically on S874 
to regulate DLK-1L activity (Figure 2-11). While PPM-2 activity is sufficient to 
inhibit transgenically overexpressed DLK-1 (Figure 2-8A), it was not sufficient to 
regulate binding of DLK-1L to DLK-1S (Figure 2-8B). This result is consistent with 
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two possible interpretations. 1) Phosphorylation of DLK-1 at S874 is required for 
activation of DLK-1, but this activation occurs through a mechanism that is 
independent of DLK-1S. 2) DLK-1L needs to be phosphorylated at both S874 
and S878 to block binding to DLK-1S and become active. In this case, DLK-1L 
would display different levels of inactivation, with dephosphorylation at both 
residues presumably being the most inactive. Such a signaling model would 
allow sophisticated spatial and temporal control over how quickly DLK-1 is 
activated. A combination of future biochemical and genetic experiments will 
hopefully support one of these two signaling models. 
 C. elegans DLK-1 has two homologs in mammals, DLK (MAP3K12) and 
LZK (MAP3K13) both of which are highly expressed in brain (Holzman et al., 
1994; Sakuma et al., 1997). While DLK plays an important role in neuronal 
development and axon regeneration, our knowledge regarding LZK remains 
relatively modest. Notably, the small segment of the C. elegans DLK-1L C-
terminus that contains S874 and S878 is conserved with mammalian LZK, and 
not mammalian DLK (Yan and Jin, 2012). Thus, the mammalian functional 
ortholog of PPM-2 would be likely to regulate LZK rather than DLK.  
 Because RPM-1 binds to and positively regulates PPM-2, it is plausible 
that RPM-1 acts as a more sophisticated regulator of DLK-1 than originally 
thought by regulating long-term DLK-1 signaling (through ubiquitination) and 
short-term/local DLK-1 signaling (through the phosphatase activity of PPM-2). 
The idea that RPM-1 controls local/short-term signaling and long-term signaling 
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is supported by observations in flies and worms showing that the DLK-1 pathway 
regulates the activity of the transcription factors Fos and CEBP-1 (Collins et al., 
2006; Yan et al., 2009), and the translation of CEBP-1 locally in axons (Yan et 
al., 2009). We note that our results cannot absolutely rule out the possibility that 
dephosphorylation of DLK-1 by PPM-2 is a prerequisite for ubiquitination and 
degradation of DLK-1 by an RPM-1/FSN-1 ligase complex. However, our finding 
that ppm-2 and fsn-1 function in parallel genetic pathways makes this extremely 
unlikely.  
 It remains important to address how RPM-1 determines whether to 
degrade DLK-1, or act through PPM-2 to dephosphorylate DLK-1. This may be 
based on developmental timing, the subcellular location of DLK-1, the activation 
state of DLK-1, post-translational modification of DLK-1, or a combination of 
these factors. Upstream signals may also instruct RPM-1 to degrade or 
dephosphorylate DLK-1. A better understanding of the mechanisms and 
molecules that activate RPM-1 and DLK-1 are likely to be helpful in addressing 
these possibilities.  
 Since both PPM-2 and PPM-1 negatively regulate the DLK-1 pathway, we 
attempted to analyze the genetic relationship between ppm-2 and ppm-1. 
Unfortunately, ppm-2-/-; ppm-1-/- double mutants were embryonic lethal in the F2 
generation (data not shown), which rendered our genetic analysis inconclusive. 
However, the synthetic lethality observed between ppm-2 (lf) and ppm-1 (lf) is 
consistent with these phosphatases acting on different targets. This agrees with 
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our prior study that suggested PPM-1 acts at the level of the p38 MAP kinase 
PMK-3 (Tulgren et al., 2011), and our work here demonstrating that PPM-2 acts 
on DLK-1. Several other pieces of evidence support the conclusion that PPM-2 
and PPM-1 act on different targets in the DLK-1 pathway. The primary phenotype 
in ppm-2-/- animals was low penetrance hook defects in PLM neurons, while we 
previously showed that ppm-1-/- mutants primarily display low penetrance 
overextension defects in PLM neurons (Tulgren et al., 2011). Since the hook 
phenotype is more severe (Grill et al., 2007; Grill et al., 2012), our results are 
consistent with PPM-2 acting higher up in the kinase cascade than PPM-1. This 
model is further supported by our observation that ppm-2-/- fsn-1-/- double 
mutants show stronger enhancement of hook defects (Figure 2-2D) compared to 
ppm-1-/-; fsn-1-/- double mutants (Tulgren et al., 2011). Nonetheless, further 
biochemical and transgenic studies will be needed to definitively determine if 
PPM-2 and PPM-1 act at different points in the DLK-1 pathway. 
 
2.3.3 N-myristoylation and PPM-2 
Previous studies have shown that several types of phosphatases are 
myristoylated (Aitken et al., 1982; Alonso et al., 2004; Chida et al., 2013; 
Schwertassek et al., 2010). Our mass spectrometry and transgenic results 
indicated that N-myristoylation is also required for PPM-2 to be fully functional. 
Our findings are consistent with prior observations on PP2C phosphatases. First, 
other PP2C phosphatases have N-myristoylation consensus motifs (Feng et al., 
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2010a). Second, a recent biochemical study showed that two PP2C 
phosphatases (PPM1A and PPM1B) are N-myristoylated, and myristoylation is 
required for substrate specificity, but not enzymatic activity (Chida et al., 2013). 
However, myristoylation is also known to regulate the membrane localization of 
signaling proteins. Thus, our findings coupled with these prior observations 
demonstrate that N-myristoylation is an important posttranslational modification 
that mediates the substrate specificity and/or membrane localization of PPM-2. 
We also show for the first time that myristoylation is important for the function of 
PP2C phosphatases in neurons.  
 Previous work showed that mammalian DLK is associated with the plasma 
membrane at synapses (Mata et al., 1996). While DLK in the cytosol is in both 
hyperphosphorylated and unphosphorylated forms, membrane bound DLK is 
phosphorylated to a lesser extent or unphosphorylated. Our observations that 
PPM-2 is N-myristoylated, that PPM-2 negatively regulates DLK-1, and that 
PPM-2 binds to DLK-1 suggest that PPM-2 may act at the plasma membrane of 
the presynaptic terminal to regulate the phosphorylation of DLK-1. This model is 
consistent with our observation that PPM-2 is localized to the presynaptic 
terminal (see Figure 8). Alternatively, N-myristoylation may regulate the target 
specificity of PPM-2 and, therefore, PPM-2 activity on DLK-1.  
 
2.3.4 Conclusion 
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We now provide evidence that RPM-1 is potentially a more sophisticated 
regulator of DLK-1 than originally thought. While this is a significant step forward, 
important questions remain: 1) Does RPM-1 regulate molecules other than DLK-
1 in a more precise and accurate manner, possibly through PPM-2 or other 
mechanisms? 2) How is RPM-1 activity regulated, and do upstream extracellular 
guidance cues, morphogens, or adhesion molecules instruct the activity of RPM-
1 during neuronal development? 3) Is RPM-1 located in multiple subcellular 
compartments in a single neuron, which may explain the dual role of RPM-1 in 
axon termination and synapse formation? Addressing these questions will be 
essential to further support the previously proposed model that RPM-1 and the 
PHR proteins function to coordinate different events in neuronal development (Li 
et al., 2008; Po et al., 2010). 
 
2.4 Materials and Methods 
2.4.1 Genetics 
 The N2 isolate of C. elegans was propagated using standard procedures. The 
alleles used in this study included: rpm-1(ju44), fsn-1(gk429), glo-4(ok623), dlk-
1(ju476), ppm-2(ok2186), ppm-2(tm3480), unc-32(e189), unc-103(e1597), dpy-
17(e164), and lon-1(e1820). For generation of transheterozygous ppm-
2(ok2186)/ppm-2(tm3480) fsn-1 double mutants, tm3480 was linked to unc-
32(e189) and ok2186 was linked to lon-1(e1820). Transheterozygous animals 
were identified as non-lon, non-unc animals. ppm-2(ok2186) fsn-1 and ppm-
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2(tm3480) fsn-1 double mutants were constructed by recombination using 
ok2186 and tm3480 linked to dpy-17(e164) and fsn-1 linked to unc-103(e1597).   
  
2.4.2 Transgenics  
Transgenic animals were generated by standard microinjection procedures.  All 
transgenes were constructed by injection of plasmid or DNA generated by PCR 
with Pttx-3RFP (50 ng/µL) or Pmyo-2mCherry (2.5 ng/µL) and pBluescript (50 
ng/µL). Injection conditions and genotypes for all transgenes are provided upon 
request. For all transgenic and biochemical experiments, a cDNA encoding 
isoform B of DLK-1 was used. Point mutants of DLK-1 (S874E and S878E) were 
annotated based on isoform A for continuity of presentation with previous 
studies, but these residues correspond to S867 and S871 in isoform B.  
 
2.4.3 Biochemistry and mass spectrometry  
Purification of RPM-1::GFP from transgenic C. elegans and identification of 
associated RPM-1 binding proteins by mass spectrometry was described 
previously (Grill et al., 2007).  In brief, transgenic mixed stage C. elegans were 
grown in liquid cultures using M9 buffer supplemented with cholesterol and 
HB101 E. coli. Worms were washed repeatedly in fresh M9 buffer, and pelleted 
by low speed centrifugation. Frozen worms were ground under liquid N2 with a 
mortar and pestle, and extracted with 0.1% NP-40 lysis buffer (10mM Tris pH 
7.4, 0.1% NP-40, 150mM NaCl, 1mM DTT, protease and phosphatase 
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inhibitors). GFP::RPM-1 was immunoprecipitated from worm extracts using an 
anti-GFP antibody (3E6 mouse monoclonal, Qbiogene), run on an SDS-PAGE 
gel, and proteins coprecipitating with GFP::RPM-1 were identified by LC-MS/MS.  
 For coIP of RPM-1 and PPM-2, worms were lysed in 0.1% NP-40 lysis 
buffer (50mM Tris pH 7.5, 0.1% NP-40, 150 mM NaCl, 10% glycerol, protease 
inhibitors, and phosphatase inhibitors: microcystin, NaVO4, NaF, NaMolybdate, 
and b-glycerophosphate). For coIP, transgenic proteins were immunoprecipitated 
with an anti-FLAG antibody (M2 mouse monoclonal, Sigma) or an anti-GFP 
antibody (3E6 mouse monoclonal, MP Biomedicals) and protein G agarose. 
Coprecipitating GFP fusion proteins or FLAG tagged proteins were detected by 
immunoblotting with an anti-GFP antibody (Roche, mouse monoclonal) or an 
anti-FLAG antibody (rabbit monoclonal, Cell Signaling), respectively. 3 mg of 
total worm lysate was used for coIP of FLAG::PPM-2 with RPM-1::GFP. 5mg of 
total worm lysate was used for coIP of wild-type or mutant PPM-2::GFP with 
FLAG::DLK-1 K162R. 10mg of total worm lysate was used for coIP of GFP::DLK-
1S with FLAG:DLK-1L K162R. 
 For immunoblot analysis of whole C. elegans lysates, samples were 
prepared as described previously (Saha and Wolozin, 2011). Animals were age-
synchronized by bleach treatment. Array positive young adults were selected 
using Pttx-3RFP and cleaned by transferring to an NGM plate with no bacteria. 50 
animals were picked for each genotype and placed into a tube with 20µL of 
water. Samples were mixed with 20µL of 2X Laemmli Sample Buffer (Biorad) 
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with 2-βmercaptoethanol. Animals were pelleted by centrifugation and samples 
were flash frozen in liquid nitrogen. Prior to immunoblotting, samples were 
incubated at 95oC for 5 minutes, cooled for 5 minutes at room temperature, and 
loaded onto an SDS-PAGE gel. GFP fusion or FLAG tagged proteins were 
detected by immunoblotting with an anti-GFP antibody (Roche, mouse 
monoclonal) or an anti-FLAG antibody (rabbit monoclonal, Cell Signaling), 
respectively. MPK-1 (Erk1) was detected by immunoblotting with an anti-ERK1 
antibody (K-23 rabbit polyclonal, Santa Cruz Biotechnology) and mCherry was 
detected by immunoblotting with an anti-mCherry antibody (mouse monoclonal, 
Clontech). 
 Immunoblots from coIP and whole cell lysates were visualized using 
secondary antibodies coupled to horseradish peroxidase, Supersignal 
FemtoWest chemiluminescent reagent (Pierce), and x-ray film. Western 
Lightning Plus-ECL (PerkinElmer) was used for anti-Erk immunoblotting of MPK-
1. Quantitation of bands in immunoblots of whole worm lysates and coIP 
experiments was performed using image J software from NIH image 
(http://rsb.info.nih.gov/ij/). 
 
2.4.4  Axon termination and synapse formation analysis  
For analysis of GFP or SNB-1::GFP, live young adult animals (16-20 hours post 
L4)  were anesthetized using 1% (v/v) 1-phenoxy-2-propanol in M9 buffer and 
visualized using a 40x magnification oil-immersion lens and an epifluorescent 
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microscope (Nikon Eclipse E40). Images were acquired using a CCD camera (Q-
imaging Qicam 1394). Axon termination defects in the mechanosensory neurons 
were quantified by manually scoring muIs32 (Pmec-7GFP). Synapse formation 
defects were quantified by collecting images of juIs1 (Punc-25SNB-1::GFP), and 
manually scoring puncta numbers in acquired images using Adobe Photoshop. 
The mechanosensory neurons were analyzed at 23oC, as previous studies 
showed that axon termination defects in PLM neurons are maximally defective at 
23oC (Grill et al., 2007; Schaefer et al., 2000). While ALM axon termination and 
PLM synaptic branch extension are temperature sensitive processes, 23oC is a 
sufficient temperature to achieve strong phenotypes. Synapse formation in 
GABAergic neurons was analyzed at 25oC because a previous study showed 
that the ju44 allele of rpm-1 is temperature sensitive with regard to this process, 
and gives a maximal phenotype at 25oC (Zhen et al., 2000). 
 
2.4.5 Confocal microscopy 
Colocalization of SNB-1::dsRED and PPM-2::GFP (bggEx88) was analyzed 
using a Zeiss 780 laser scanning confocal microscope at 63x magnification under 
immersion oil. Images were acquired using Zeiss Zen software, and analyzed 
using Image J. Young adult animals were analyzed in all cases. 
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3 Neuronal Development in Caenorhabditis elegans is Regulated by 
Inhibition of an MLK MAP Kinase Pathway 
Content adapted from published article: Baker ST, Turgeon SM, Tulgren 
ED, Wigant J, Rahimi O, Opperman KJ, Grill B (2015) Neuronal 
development in C. elegans is regulated by inhibition of an MLK MAP kinase 
pathway. Genetics 199:151-156 
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3.1 Introduction 
In C. elegans, the ubiquitin ligase Regulator of Presynaptic Morphology 1 (RPM-
1) regulates neuronal development by inhibiting the DLK-1 pathway (composed 
of DLK-1, MKK-4, and PMK-3) (Nakata et al., 2005). RPM-1 and the DLK-1 
pathway regulate axon regeneration post-developmentally (Hammarlund et al., 
2009; Yan et al., 2009). The MLK-1 pathway, which includes the kinases MLK-1, 
MEK-1, and KGB-1/JNK, also regulates axon regeneration (Nix et al., 2011). It 
remains unclear if RPM-1 functions through the MLK-1 pathway to regulate 
development. 
 Protein Phosphatase Mg/Mn2+ dependent 1 (PPM-1) and PPM-2 
negatively regulate the DLK-1 pathway (Baker et al., 2014; Tulgren et al., 2011). 
PPM-2 is regulated by RPM-1 and dephosphorylates full-length DLK-1 (DLK-1L). 
PPM-1 is likely to function lower in the DLK-1 pathway. It remains unclear 
whether PPM-1 and PPM-2 regulate other signaling pathways in the neurons of 
C. elegans.  
 Here, we show that mutations in mlk-1, mek-1, and kgb-1/jnk suppress 
defects in synapse formation and axon termination caused by rpm-1 loss of 
function (lf). These results suggest that RPM-1 might negatively regulate the 
MLK-1 pathway, which is consistent with our observation that transgenic 
overexpression of MLK-1 or KGB-1 caused axon termination defects. Further, 
our results are consistent with PPM-1 negatively regulating the MLK-1 pathway, 
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in addition to inhibiting the DLK-1 pathway. In contrast, our findings suggested 
that PPM-2 only acts on DLK-1L. 
 
3.2 Results 
3.2.1 Loss-of-function mutations in kinases of the MLK-1 pathway 
suppress defects in synapse formation caused by rpm-1 (lf) 
The fly ortholog of RPM-1, called Highwire, functions through JNK to regulate 
synapse formation (Collins et al., 2006). It is unclear if RPM-1 functions through 
JNK to regulate synapse formation in worms, but studies on axon regeneration 
suggested that this might be a possibility (Nix et al., 2011). Hence, we assessed 
the genetic relationship between kinases of the MLK-1 pathway, including kgb-
1/jnk, and rpm-1 in the context of synapse formation.  
 Consistent with previous studies, the GABAergic motor neurons of rpm-1-
/- mutants had synapse formation defects that were strongly, but incompletely, 
suppressed in rpm-1-/-; dlk-1-/- double mutants (Figure 3-1A and B) (Nakata et 
al., 2005). In double mutants of rpm-1 with mlk-1, mek-1 or kgb-1, significant but 
modest suppression occurred (Figure 3-1A and B). rpm-1-/- mlk-1-/-; kgb-1-/- 
triple mutants did not show increased suppression, demonstrating that mlk-1 and 
kgb-1 function in the same genetic pathway (Figure 3-1B). rpm-1-/- mlk-1-/-; dlk-1 
triple mutants showed a small, but significant increase in suppression, consistent 
with mlk-1 and dlk-1 functioning in partially redundant pathways (Figure 3-1B).  
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Figure 3-1. Loss-of-function mutations in kinases of the MLK-1 pathway suppress 
synapse formation defects in rpm-1 mutants.  
(A) Defects in synapse formation in the GABAergic motor neurons were analyzed using a 
transgene, juIs1 (Punc-25SNB-1::GFP), and epifluorescent microscopy under 40x magnification. 
rpm-1 mutants had abnormal synapse formation with aggregated synapses (arrowheads) and 
gaps in the dorsal cord (arrows). Defects caused by rpm-1 (lf) were partially suppressed by 
loss of function in mlk-1, mek-1, or kgb-1. Scale bar is 10µm. (B) Quantitation of synapse 
formation defects in GABAergic motor neurons for the indicated genotypes. Alleles used 
included: rpm-1 (ju44), dlk-1 (ju476), mlk-1 (ok2471), mek-1 (ks54), and kgb-1 (um3). Shown 
are averages for data collected from 3 or more independent experiments performed at 25oC in 
which 15-20 synchronized, young adult worms were analyzed. Error bars represent the 
standard error of the mean, and significance was determined using an unpaired Student’s t-
test. ***P<0.001, *P<0.05, and ns = not significant  
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 These results are consistent with RPM-1 regulating synapse formation by 
inhibiting both the DLK-1 and MLK-1 pathways. Notably, these findings do not 
rule out the possibility that kinases in the MLK-1 pathway function in a parallel 
genetic pathway to rpm-1. 
 
3.2.2 Mutations in kinases of the MLK-1 pathway suppress axon 
termination defects caused by rpm-1 (lf) 
Two types of axon termination defects are present in the PLM mechanosensory 
neurons of rpm-1-/- mutants (Grill et al., 2007; Schaefer et al., 2000; Tulgren et 
al., 2011). 1) Severe, highly penetrant defects in which an axon overextends and 
hooks towards the ventral cord, referred to as hook defects (Figure 3-2A and B). 
2) Rarely observed, milder defects in which an axon overextends but fails to hook 
ventrally, referred to as overextension defects. Hook defects were strongly 
suppressed in rpm-1-/-; dlk-1-/- double mutants (Figure 3-2B). In double mutants 
of rpm-1 with mlk-1, mek-1, or kgb-1 the frequency of hook defects was 
moderately suppressed, while the expressivity of less severe overextension 
defects was increased (Figure 3-2A and B). These effects were not increased in 
rpm-1-/- mlk-1-/-; kgb-1-/- triple mutants (Figure 3-2B). Transgenic expression of 
MLK-1 specifically in the mechanosensory neurons rescued the suppression in 
rpm-1-/- mlk-1-/- double mutants (Figure 3-2C).  
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Figure 3-2. Axon termination defects in rpm-1 mutants are suppressed by loss of 
function in mlk-1, mek-1, or kgb-1.  
(A) Shown is a schematic of the mechanosensory neurons of C. elegans (adapted from Baker 
et al., 2014). Axon termination of the PLM mechanosensory neurons was analyzed using a 
transgene, muIs32 (Pmec-7GFP), and epifluorescent microscopy under 40x magnification. 
Shown are representative images of a more severe axon termination defect in a rpm-1 mutant 
in which the PLM neuron overextends beyond the ALM cell body and hooks towards the 
ventral cord (hook, arrowhead), and a less severe axon termination defect in a fsn-1 mutant 
and in a rpm-1; kgb-1 double mutant in which the PLM axon only overextends beyond the 
ALM cell body (overextension, arrow). Note that the AVM cell body is only present on one side 
of the animal and is not always shown. Scale bar is 10µm.  
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These results show that mlk-1, mek-1, and kgb-1 function cell 
autonomously in the same genetic pathway to suppress rpm-1 (lf). These 
findings are also consistent with RPM-1 negatively regulating the MLK-1 
pathway. 
 
3.2.3 fsn-1 (lf) is suppressed by mutations in kinases of the DLK-1 
pathway, but not in kinases of the MLK-1 pathway 
RPM-1 functions as a complex with the F-box protein FSN-1 to regulate PLM 
axon termination (Grill et al., 2007; Liao et al., 2004). Axon termination defects in 
fsn-1-/- mutants were suppressed in fsn-1-/-; dlk-1-/- and fsn-1-/-; pmk-3-/- 
double mutants (Figure 3-2D) (Baker et al., 2014). In contrast, the frequency of 
(B) Quantitation of PLM axon termination defects (hook in black, overextension in grey) for the 
indicated genotypes. Note that double mutants of rpm-1 and kinases in the MLK-1 pathway 
result in a reduction in hook defects and increased expressivity of less severe overextension 
defects. (C) Transgenic expression of MLK-1 using a promoter that is specifically expressed in 
mechanosensory neurons (Pmec-7) rescues suppression of severe hook defects and rescues 
increased expressivity of less severe overextension defects in rpm-1 mlk-1 double mutants. 
Rescue does not occur with transgenic expression of a control protein, mCherry. (D) 
Quantitation of PLM axon termination defects for the indicated genotypes. Note that fsn-1 (lf) 
is not suppressed by mlk-1 or kgb-1 (lf). (E) Representative images are shown for a PLM 
neuron from transgenic animals overexpressing the indicated kinases using a pan-neuronal 
promoter (Prgef-1). A more severe hook defect is highlighted with an arrowhead, and less 
severe overextension defects are highlighted with arrows. (F) Quantitation of the PLM axon 
termination defects caused by transgenic overexpression of the indicated kinases. Shown are 
different concentrations of the indicated PCR products that were injected to generate 
extrachromosomal arrays. Notably, the molar ratios of constructs were similar with the 
exception of mlk-1, which was 1.6 times larger than other constructs. Transgenic animals were 
generated by microinjecting a mixture of PCR product encoding the indicated construct, 
50ng/µL of Pttx-3::RFP (coinjection marker), and 50ng/µL of pBluescript. Injection conditions 
and genotypes for all transgenes are available upon request 1. Averages are shown for data 
collected from 5-8 independent counts of 20-30 PLM neurons from young adult worms grown 
at 23oC. For transgenic genotypes, averages shown are data pooled from 4 or more 
independent lines. Alleles used included: rpm-1 (ju44), fsn-1 (gk429), dlk-1 (ju476), pmk-3 
(ok169), mlk-1 (ok2471), mek-1 (ks54), and kgb-1 (um3). Error bars represent the standard 
error of the mean, and significance was determined using an unpaired Student’s t-test. 
***P<0.001, **P<0.01, *P<0.05, and ns = not significant 
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axon termination defects remained unchanged in fsn-1-/-; mlk-1-/- or fsn-1-/-; 
kgb-1-/- double mutants (Figure 3-2D). These findings are consistent with FSN-1 
inhibiting the DLK-1 pathway, but not the MLK-1 pathway.  
 
3.2.4 Excess MLK-1 pathway function impairs axon termination 
One explanation for why rpm-1 (lf) is suppressed by mutations in the MLK-1 
pathway is that rpm-1 mutants have excess, unchecked MLK-1 pathway function. 
To test this hypothesis, we generated transgenic animals with extrachromsomal 
arrays that expressed different kinases in the DLK-1 and MLK-1 pathways. To 
assess the range of defects that might be caused by kinase overexpression, we 
generated arrays with varying levels of DNA encoding different kinases. For 
MLK-1 and KGB-1, we observed primarily less severe overextension defects, 
and very low, but significant, levels of hook defects at higher concentrations 
(Figure 3-2E and F). Similar results were observed with overexpression of PMK-3 
(Figure 3-2E and F). In contrast, overexpression of DLK-1L caused more severe 
hook defects, which occurred with increasing frequency as the concentration of 
DLK-1L increased (Figure 3-2E and F) (Baker et al., 2014; Tulgren et al., 2011). 
We did not analyze MKK-4, but previous work showed that MKK-4 
overexpression causes an intermediate frequency of hooks (Baker et al., 2014). 
These results provide further support for the model that RPM-1 negatively 
regulates the MLK-1 pathway.  
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3.2.5 Analysis of PPM-1 and PPM-2 function on the MLK-1 pathway 
The phosphatases PPM-1 and PPM-2 negatively regulate the DLK-1 pathway 
(Baker et al., 2014; Tulgren et al., 2011). Using a combination of suppressor 
genetics and transgenics, we tested whether PPM-1 and/or PPM-2 affect the 
function of the MLK-1 pathway.  
 Previously, we found that ppm-2-/- mutants had very low penetrance hook 
defects, which were completely suppressed in ppm-2-/-; dlk-1-/- double mutants 
(Baker et al., 2014). In contrast, hook defects were not suppressed in ppm-2-/-; 
mlk-1-/- or ppm-2-/-; kgb-1-/- double mutants (Figure 3-3A). In the case of ppm-1-
/- mutants which lack hooks defects, we utilized a glo-4 (lf) sensitizing 
background which is enhanced by ppm-1 (lf) (Figure 3-4A) (Tulgren et al., 2011). 
Figure 3-3. PPM-2 does not regulate the MLK-1 pathway.  
(A) Quantitation of PLM axon termination defects (hook) for the indicated genotypes. Alleles 
used included: mlk-1 (ok2471), kgb-1 (um3), and ppm-2 (ok2186). Shown are averages for 
data collected from 5-8 independent counts of 20-30 PLM neurons. (B) Quantitation of the 
PLM axon termination defects (overextension) caused by transgenic overexpression of MLK-1 
(5ng/µL PCR product) or KGB-1 (10ng/µL PCR product) using the pan-neuronal rgef-1 
promoter. Note that transgenic coexpression of PPM-2 (5ng/µL plasmid) using the mec-7 
promoter, which is specifically expressed in mechanosensory neurons, fails to rescue defects 
caused by expression of MLK-1 or KGB-1. Shown are averages for data pooled from 4 or 
more transgenic lines for the indicated genotypes. In all cases, young adult worms grown at 
23oC were analyzed. Error bars represent the standard error of the mean, and significance 
was determined using an unpaired Student’s t-test. ***P<0.001 and ns = not significant 
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The enhanced frequency of hooks present in ppm-1-/- glo-4-/- double mutants 
was suppressed in ppm-1-/- glo-4-/- mlk-1-/- and ppm-1-/- glo-4-/-; kgb-1-/- triple 
mutants (Figure 3-4A). In contrast, hook defects in glo-4-/- mutants were not 
suppressed in glo-4-/- mlk-1-/- and glo-4-/-; kgb-1-/- double mutants.  
 Next, we analyzed whether PPM-1 and PPM-2 regulate the MLK-1 
pathway in the context of transgenic overexpression experiments. As shown in 
Figure 3-3B, transgenic overexpression of MLK-1 or KGB-1 resulted in axon 
termination defects, and coexpression of PPM-2 in the same transgenic arrays 
did not affect MLK-1 or KGB-1 functional efficacy. In contrast, transgenic 
coexpression of PPM-1 significantly reduced the defects caused by 
overexpression of MLK-1 and KGB-1 (Figure 3-4B). Consistent with the previous 
findings on DLK-1L (Tulgren et al., 2011), defects caused by transgenic 
overexpression of PMK-3 were reduced by transgenic coexpression of PPM-1 
(Figure 3-4B). Importantly, catalytically inactive PPM-1 D246N did not reduce 
defects caused by overexpression of MLK-1 or KGB-1. Thus, PPM-1 
phosphatase activity regulates excess MLK-1 pathway function, and the 
reduction caused by coexpression of PPM-1 was not an indirect consequence of 
incorporating a second gene into extrachromosomal arrays (Figure 3-4B).  
 Collectively, these results are consistent with PPM-1 phosphatase activity 
inhibiting both the DLK-1 and the MLK-1 pathways. In contrast, these results 
suggest that PPM-2 is more specific for DLK-1L, and not capable of regulating 
the MLK-1 pathway.  
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Figure 3-4. PPM-1 functions to inhibit the MLK-1 and DLK-1 pathways.  
(A) Quantitation of PLM axon termination defects (hook) for the indicated genotypes. Alleles 
used included: mlk-1 (ok2471), kgb-1 (um3), ppm-1 (ok578), glo-4 (ok623). Shown are 
averages for data collected from 5-8 independent counts of 20-30 PLM neurons. (B) 
Quantitation of the PLM axon termination defects (overextension) caused by transgenic 
overexpression of MLK-1 (5ng/µL PCR product), KGB-1 (10ng/µL PCR product), or PMK-3 
(10ng/µL PCR product) using the pan-neuronal rgef-1 promoter. Note that transgenic 
coexpression of PPM-1 (2ng/µL plasmid) using the mec-7 promoter rescues defects caused 
by expression of all kinases. (C) Signaling model of the DLK-1 and MLK-1 pathways with 
regulatory mechanisms that function during neuronal development. Because rpm-1 (lf), but not 
fsn-1 (lf), is suppressed by kinases in the MLK-1 pathway, we speculate that should RPM-1 
ubiquitinate and inhibit MLK-1, it would be likely to do so through a presently unknown F box 
protein.  ***P<0.001, **P<0.01, and ns = not significant 
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3.3 Discussion 
RPM-1 is an important signaling molecule that regulates neuronal development 
through multiple mechanisms (Baker et al., 2014; Grill et al., 2007; Grill et al., 
2012; Tulgren et al., 2014), including ubiquitination and inhibition of DLK-1L 
(Nakata et al., 2005). Our genetic suppressor analysis and transgenic results 
suggest that RPM-1 also negatively regulates the MLK-1 pathway during 
development. Our findings are consistent with a previous study, which showed 
that MLK-1 levels are increased in the neurons of rpm-1 (lf) mutants (Nix et al., 
2011). One simple explanation for these findings is that RPM-1 ubiquitinates 
MLK-1, which results in MLK-1 degradation and inhibition of the MLK-1 pathway 
(Figure 3-4C). However, an alternative explanation for our results is that the 
MLK-1 pathway functions in parallel to RPM-1. Because mutations in kinases of 
the DLK-1 pathway are stronger suppressors of rpm-1 (lf) than mutations in 
kinases of the MLK-1 pathway, it is likely that RPM-1 functions primarily through 
the DLK-1 pathway, and secondarily through the MLK-1 pathway (Figure 1 and 
2) (Nakata et al., 2005). 
 Our results are consistent with the PPM-1 phosphatase representing a 
further, conserved negative regulatory mechanism imposed on the DLK-1 and 
MLK-1 pathways (Figure 3-4C). In contrast, we found no evidence that PPM-2 
regulates the MLK-1 pathway. Therefore, taking prior work into account, PPM-2 
is likely to be a relatively specific mechanism for restraining DLK-1L activity 
(Baker et al., 2014). 
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 During neuronal development, JNK and p38 MAP kinases mediate the 
function of Drosophila Highwire and mammalian Phr1 (Collins et al., 2006; 
Huntwork-Rodriguez et al., 2013; Klinedinst et al., 2013; Lewcock et al., 2007). 
Given prior work and our findings here, it is increasingly likely that the 
Pam/Highwire/RPM-1 (PHR) protein family generally regulates two MAP kinase 
pathways exemplified by the DLK-1 and MLK-1 pathways in C. elegans.   
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4 Identification of a Peptide Inhibitor of the RPM-1/FSN-1 
Ubiquitin Ligase Complex 
This research was originally published in The Journal of Biological 
Chemistry. Sharma J*, Baker ST*, Opperman KJ, Turgeon SM, Gurney 
AM, Opperman KJ, Grill B. Identification of a Peptide Inhibitor of the RPM-
1/FSN-1 Ubiquitin Ligase Complex. The Journal of Biological Chemistry. 
2014; Vol 289: 34654-34666. © The American Society for Biochemistry and 
Molecular Biology. 
*Both authors contributed equally. Figure by figure contributions listed in 
author contributions section at end of chapter. 
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4.1 Introduction 
C. elegans Regulator of Presynaptic Morphology 1 (RPM-1) along with 
Drosophila Highwire, murine Phr1, and human Pam (MCYBP2) are part of a 
conserved family of E3 ubiquitin ligases referred to as Pam/Highwire/RPM-1 
(PHR) proteins (Po et al., 2010). Studies in worms, flies, fish, and mice have 
identified roles for the PHR proteins in synapse formation (Burgess et al., 2004; 
Schaefer et al., 2000; Wan et al., 2000; Zhen et al., 2000), axon guidance and 
extension (Bloom et al., 2007; Culican et al., 2009; D'Souza et al., 2005; 
Lewcock et al., 2007; Li et al., 2005; Shin and DiAntonio, 2011), and axon 
termination (Grill et al., 2007; Kim et al., 2013; Refai et al., 2013; Schaefer et al., 
2000). 
 The PHR proteins function through multiple signaling mechanisms to 
control neuronal development, one of which is ubiquitination, and negative 
regulation of the MAP3K Dlk (DLK-1 in worms and Wallenda in flies) (Collins et 
al., 2006; Huntwork-Rodriguez et al., 2013; Lewcock et al., 2007; Nakata et al., 
2005). In C. elegans, RPM-1 functions as part of an ubiquitin ligase complex that 
includes F-box Synaptic protein 1 (FSN-1) (Liao et al., 2004). The functional 
relationship between RPM-1 and FSN-1 is conserved in flies and mammals 
(Saiga et al., 2009; Wu et al., 2007).  
 Despite significant and important progress with genetic approaches, our 
knowledge of the structure-function relationship between PHR proteins and F-
box proteins, such as FSN-1, remains limited. Nonetheless, knowledge gained 
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from structure-function analysis is likely to be valuable for developing specific 
inhibitors of PHR ubiquitin ligase complexes. Studies in worms and flies have 
shown that inhibiting PHR protein function results in improved axon regeneration 
(Hammarlund et al., 2009; Nix et al., 2011; Xiong et al., 2010), and reduced axon 
degeneration following trauma (Babetto et al., 2013; Xiong et al., 2012). Thus, an 
inhibitor that specifically blocks the PHR ubiquitin ligase complex might prove 
valuable for improving axon regeneration, and reducing axon degeneration in the 
context of trauma and disease. 
 Here, we detail our discovery of a 97 amino acid (aa) region of RPM-1 that 
is sufficient for binding to FSN-1. The conservation of key residues in RPM-1 that 
mediate binding to FSN-1 suggests that this could be a conserved mechanism of 
interaction. The results of transgenic and genetic analysis are consistent with this 
peptide inhibiting the RPM-1/FSN-1 complex in vivo. Hence, we have termed it 
the RPM-1/FSN-1 complex inhibitory peptide (RIP). To our knowledge, RIP 
represents the first inhibitor of a PHR ubiquitin ligase complex. 
 
4.2 Results 
4.2.1 A single domain in RPM-1 is sufficient for binding to FSN-1  
Previous genetic and biochemical experiments have shown that C. elegans 
RPM-1 and Drosophila Hiw are part of a complex that includes the F-box protein 
FSN-1 (Liao et al., 2004; Wu et al., 2007). In mammals, the Myc binding domain 
of Pam binds to Fbxo45, the ortholog of FSN-1 (Saiga et al., 2009). Despite 
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significant progress in understanding the function of the PHR ubiquitin ligase 
complex, the biochemical mechanisms underlying the formation of this complex 
remain minimally explored.  
 Because the interaction between RPM-1 and FSN-1 is evolutionarily 
conserved, we hypothesized that FSN-1 would bind to a region in RPM-1 that 
corresponded with a conserved portion of the Myc binding domain of Pam. 
ClustalW2 analysis of the PHR proteins showed that the Myc binding domain of 
Pam (aa 2413-2712) was composed of a C-terminal region that was not present 
in Hiw or RPM-1 (Figure 4-1A, MBD), and an N-terminal region that was well 
conserved (22.4% identical and 52.3% conservation between Pam and RPM-1) 
(Figure 4-1A). This N-terminal region contained several conserved motifs that 
might mediate binding between RPM-1 and FSN-1 (Figure 4-3A). To test this 
possibility, we cloned cDNAs encoding 9 individual protein domains (D1-9) that 
represented the entire RPM-1 coding sequence (Figure 4-1A). The boundaries of 
each domain were engineered at locations where conservation was strongly 
decreased. We transiently transfected HEK 293 cells with plasmids that express 
a GFP fusion protein for each of the 9 RPM-1 domains, and FLAG epitope 
tagged FSN-1. Coimmunoprecipitation (coIP) was used to determine if FSN-1 
binds to a specific RPM-1 domain. As predicted by our bioinformatic analysis, 
FSN-1 coprecipitated with RPM-1 domain 5 (D5), which shared homology with 
the N-terminal portion of the Pam Myc binding domain (Figure 4-1B, top panel). 
We previously showed that D5 is sufficient for binding to RAE-1, so we also refer 
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to this domain as the RAE-1 binding domain (Figure 4-1A and B) (Grill et al., 
2012). We noted that coexpression of D5 with FSN-1 consistently resulted in 
increased expression of FSN-1 (Figure 4-1B and 2B, bottom panels). This result 
is consistent with prior work, which showed that the Myc binding domain of Pam 
stabilizes Fbxo45 protein levels, presumably by sequestering it from degradation 
by an endogenous E3 ligase (Saiga et al., 2009). 
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 To further map the interaction between FSN-1 and RPM-1, we generated 
smaller fragments of RPM-1 D5 (Figure 4-2A). As shown in Figure 4-2B, the N-
terminal half of D5 (D5a) did not bind to FSN-1, while the C-terminal half (D5b) 
was sufficient for binding. We then generated a smaller, 97 aa portion of D5b 
(D5c) that contained only sequence conserved with the Myc binding domain of 
human Pam. GFP-D5c coprecipitated with FLAG-FSN-1 with similar efficiency to 
GFP-D5 and GFP-D5b (Figure 4-2B).  
 To test whether this interaction occurs in vivo in neurons, we generated 
transgenic C. elegans that used a pan-neuronal promoter (Prgef-1) to 
simultaneously express both GFP::D5c and FLAG::FSN-1. As shown in Figure 4-
2C, when GFP::D5c was precipitated with an anti-GFP antibody, robust 
coprecipitation of FLAG::FSN-1 was detected. In contrast, when FLAG::FSN-1 
was expressed alone in transgenic worms, no coprecipitation occurred (Figure 4-
2C). These results demonstrate that D5c, a conserved 97 aa region of RPM-1, is 
Figure 4-1: Identification of a domain in RPM-1 that is sufficient for binding to FSN-1.  
A) Shown is a schematic of human Pam and C. elegans RPM-1. Annotated protein domains 
include: the RCC-1 like domain (RLD), two PHR family specific domains (PHR), the RAE-1 
binding domain (RBD), the Myc binding domain (MBD), nuclear localization signal (NLS), and 
the RING-H2 ubiquitin ligase domain (RING). Highlighted is a motif in the RBD that is 
essential for binding to RAE-1. The portion of the MBD in Pam next to RBD is well conserved 
with RPM-1, and the portion highlighted to the right is not conserved. Also shown are 9 cDNA 
constructs encompassing the entire length of RPM-1, each of which corresponds to an 
individual, conserved domain of RPM-1 (D1-9). Domain 5 (D5) (also called the RBD) was 
further dissected into smaller subdomains (D5a-c). B) CoIP was performed from lysates of 
transfected HEK 293 cells that expressed FLAG tagged FSN-1 (FLAG-FSN-1) or FLAG 
tagged RAE-1 (FLAG-RAE-1), and fusion proteins of GFP and RPM-1 D1-D9. Note that 
FLAG-FSN-1 coprecipitated exclusively with domain 5 of RPM-1 (GFP-D5) (top panel). 
Consistent with a previous study, FLAG-RAE-1 also coprecipitated with GFP-RPM-1 domain 5 
(GFP-D5) (top panel, last lane) (Grill et al., 2012). Shown are representatives of experiments 
that were independently performed at least three times 
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sufficient for binding to FSN-1 in a heterologous expression system and in the 
neurons of C. elegans. 
 
4.2.2 Residues in RPM-1 D5 required for binding to FSN-1 
We next wanted to identify the motifs and residues in D5c that are required for 
binding to FSN-1.  Sequence alignment using ClustalW2 identified 5 motifs in 
RPM-1 D5c that were highly conserved with Drosophila Hiw and human Pam 
(Figure 4-3A, underlined). As an initial mapping strategy, we generated GFP-D5 
Figure 4-2: RPM-1 D5 contains a 97 aa region that is sufficient for binding to FSN-1. 
A) Shown is a schematic of RPM-1 domain 5 (RPM-1 D5) and three smaller fragments of D5 
(D5a-c). B) CoIP performed from lysates of transfected HEK293 cells that expressed FLAG-
FSN-1 and fragments of RPM-1 domain 5 fused with GFP (GFP-D5a-c). Note that GFP-D5b 
and GFP-D5c coprecipitated with FLAG-FSN-1 with similar efficiency to full length GFP-D5 
(top panel). C) CoIP performed from lysates of transgenic C. elegans. FLAG::FSN-1 
coprecipitates efficiently only when coexpressed with GFP::D5c. Shown are representatives of 
experiments that were independently performed at least three times. 
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that was simultaneously point mutated at multiple residues in one of the 5 
conserved motifs. Point mutants included: WCL 2239, 2240, 2241 AAA; RL 2220, 
2221 AA; DD 2214, 2215 AA; FI 2207, 2208 AA; and G2182A, R2184A, R2186A. 
Binding of FLAG-FSN-1 to D5 point mutants was analyzed using coIP from 
lysates of transiently transfected HEK 293. GFP-D5 fusion proteins were 
precipitated from transfected cell lysates using an anti-GFP antibody. While 
FLAG-FSN-1 coprecipitated well with wild-type GFP-D5, binding was strongly 
reduced for all GFP-D5 point mutants (Figure 4-3B, top panel). Thus, all 5 
conserved motifs in RPM-1 D5 that we tested were required for binding to FSN-1.
 To further map where FSN-1 binds to RPM-1 and to minimize structural 
impacts caused by mutation of multiple residues simultaneously, we generated 
point mutants of RPM-1 D5 in which only a single amino acid was mutated to 
alanine (Figure 4-3A, boxes). This was done for three of the five motifs in D5 that 
were required for binding to FSN-1. As shown in Figure 4-3C, coprecipitation of 
FSN-1 was strongly reduced for three individual point mutants of RPM-1 D5: 
W2239A, D2214A, and F2207A. Coprecipitation of FSN-1 was more mildly 
reduced for D5 I2208A (Figure 4-3C). 
 Having used a heterologous expression system to identify specific 
residues in RPM-1 that mediate binding to FSN-1, we wanted to test if the 
corresponding point mutations in full length RPM-1 would inhibit binding to FSN-1 
in the neurons of C. elegans. To address this, we generated transgenic worms 
that coexpressed a GFP fusion protein with full length RPM-1 (RPM-1::GFP), and  
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FLAG epitope tagged FSN-1 (FLAG::FSN-1). RPM-1::GFP was expressed using 
the native rpm-1 promoter that is expressed exclusively, but broadly in neurons 
(Zhen et al., 2000). FLAG::FSN-1 was expressed using a pan-neuronal promoter 
(Prgef-1). Coprecipitating RPM-1::GFP was detected when FLAG::FSN-1 was 
immunoprecipitated from whole worm lysates (Figure 4-3D). This result is 
consistent with a prior study that used anti-FSN-1 antibodies to show that RPM-1 
binds to FSN-1 (Liao et al., 2004). RPM-1::GFP D2214A also coprecipitated with 
FLAG::FSN-1, and did not show reduced binding compared to wild-type RPM-
1::GFP (Figure 4-3D). These results suggest that FSN-1 might bind to multiple 
sites in RPM-1. We did not find another portion of RPM-1 sequence with strong 
homology to RPM-1 D5c, which suggests that the second FSN-1 binding site in 
RPM-1 utilizes a different structural mechanism.  
 Nonetheless, our biochemical results indicate that FSN-1 binds either 
directly, or through an adaptor such as a Skp, to a very precise region in RPM-1: 
Figure 4-3: Identification of conserved residues in RPM-1 D5 required for binding to 
FSN-1.  
A) Schematic of full length RPM, RPM-1 domain 5 (D5), and a portion of RPM-1 domain 5 that 
is sufficient for binding to FSN-1 (D5c). Shown below is a sequence alignment of the D5c 
region of RPM-1 with its orthologs Pam (also called MYCBP-2) and Highwire that was 
generated using ClustalW2. Underlined are portions of motifs that were mutated and analyzed 
in B. Highlighted in boxes are amino acid residues that were individually point mutated and 
analyzed in C and D. B) and C) CoIP using lysates from transfected HEK 293 cells expressing 
FLAG-FSN-1 and a fusion protein of GFP and domain 5 of RPM-1 (GFP-D5). Wild-type GFP-
D5 or the indicated point mutants were analyzed for coprecipitation with FLAG-FSN-1. Note in 
C that the point mutants of GFP-D5  W2239A, D2214A, and F2207A strongly reduced 
coprecipitation with FLAG-FSN-1 compared to wild-type GFP-D5 (top panel). The interaction 
between GFP-D5 (I2208A) and FLAG-FSN-1 was more modestly reduced. D) CoIP was 
performed from whole worm lysates of transgenic C. elegans expressing FLAG::FSN-1 and 
wild-type RPM-1::GFP or RPM-1::GFP point mutated to inhibit binding to FSN-1 (RPM-1 
D2214A). Note that wild-type RPM-1::GFP and RPM-1::GFP D2214A coprecipitate with 
FLAG::FSN-1 equally. Shown are representatives of experiments that were independently 
performed at least three times 
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the D5c fragment, which we refer to as the FSN-1 binding domain 1 (FBD1) in 
the context of full length RPM-1. Moreover, our findings suggest that the D5c 
peptide might block the interaction between endogenous RPM-1 and FSN-1 in 
vivo potentially making it a highly specific inhibitor of the RPM-1/FSN-1 ubiquitin 
ligase complex. Therefore, when D5c is expressed recombinantly, we refer to it 
as RIP or the RPM-1/FSN-1 complex inhibitory peptide. 
 
4.2.3 Transgenic expression of RIP inhibits axon termination and synapse 
formation 
Previous studies have shown that rpm-1, fsn-1, and glo-4 loss-of-function (lf) 
mutants have defects in axon termination and synapse formation in the 
mechanosensory neurons of C. elegans (Grill et al., 2007; Schaefer et al., 2000). 
Further, fsn-1 and glo-4 function in parallel genetic pathways to mediate the 
function of rpm-1 (Grill et al., 2007). The genetic relationship between fsn-1 and 
glo-4, and our biochemical results showing that RIP (D5c) binds to FSN-1, 
provided a basis for determining whether exogenous expression of RIP would 
inhibit the function of the endogenous RPM-1/FSN-1 ubiquitin ligase complex. To 
test this hypothesis, we analyzed how transgenic overexpression of RIP affects 
axon termination in the mechanosensory neurons that sense soft touch in C. 
elegans. 
 In C. elegans, there are two Posterior Lateral Microtubule (PLM) 
mechanosensory neurons each of which extends a single axon that terminates 
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extension well before the cell body of the Anterior Lateral Microtubule (ALM) 
mechanosensory neurons (Figure 4-4A). The morphology of the PLM neurons 
can be rapidly and accurately analyzed using a transgene, muIs32 (Pmec-7GFP), 
which expresses GFP specifically in the mechanosensory neurons (Ch'ng et al., 
2003).  In fsn-1-/- or glo-4-/- single mutants, two axon termination phenotypes 
were observed in the PLM neurons consistent with prior studies. The primary, 
most frequent phenotype was a less severe defect in which the PLM axon failed 
to terminate extension and grew past the ALM cell body, a defect we refer to as 
overextension (Figure 4-4A and B) (Grill et al., 2007; Tulgren et al., 2011). A 
second, more severe phenotype in which the PLM axon overextended and then 
hooked towards the ventral cord, which we refer to as a hook defect, was also 
observed but at very low expressivity (Figure 4-4B). Similar to prior work, we 
observed that fsn-1-/-; glo-4-/- double mutants had strongly enhanced 
expressivity of hook defects, which was the primary phenotype in these animals 
(Figure 4-4A and B) (Grill et al., 2007; Tulgren et al., 2011). The frequency of 
hook defects in fsn-1-/-; glo-4-/- double mutants is similar to rpm-1-/- mutants 
(Grill et al., 2007; Schaefer et al., 2000; Tulgren et al., 2011).  
 To determine whether RIP inhibits the function of the endogenous RPM-
1/FSN-1 complex, we used a transgenic approach in which the rgef-1 promoter 
(a strong, pan-neuronal promoter) was used to overexpress RIP. If RIP inhibits 
the RPM-1/FSN-1 complex, we expected transgenic overexpression of RIP to 
yield phenotypes that were similar to fsn-1 (lf) mutations. Notably, we did not  
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expect RIP overexpression to yield phenotypes that occurred with the same 
expressivity as rpm-1 (lf) because RPM-1 functions through several FSN-1 
independent mechanisms including: the GLO Rab pathway, the microtubule 
binding protein RAE-1, the phosphatase PPM-2, and the ANC-1/β-catenin 
pathway (Baker et al., 2014; Grill et al., 2007; Grill et al., 2012; Tulgren et al., 
2014). We generated transgenic animals that overexpressed FLAG epitope 
tagged RIP by injecting PCR product at relatively high concentrations (10ng/µL). 
As a control for promoter effects, we also generated transgenes that 
overexpressed mCherry. The primary phenotype observed when RIP was 
transgenically overexpressed in wild-type animals was overextension of the PLM 
Figure 4-4: Transgenic overexpression of RIP (RPM-1 D5c) inhibits axon termination in 
the PLM neurons of C. elegans.  
A) A schematic (adapted from Baker et al., 2014) showing the mechanosensory neurons of C. 
elegans (anterior left, dorsal top). The box highlights the region of the animal shown below, 
which was visualized using muIs32 (Pmec-7GFP) and epifluorescent microscopy. Note that the 
AVM cell body is only present on one side of the animal and is not always shown. Images are 
shown for the most prevalent phenotype observed for each genotype. Shown are two different 
types of PLM axon termination defects: overextension (arrow), and more severe hook defects 
(arrowhead). Note that transgenic overexpression (OE) of RIP on a wild-type background 
primarily resulted in overextension, where as overexpression of RIP on a glo-4 mutant 
background primarily resulted in a more severe hook defect. B) Quantitation of PLM axon 
termination defects for the indicated genotypes (overextension in grey, hook in black). C) 
Analysis of PLM axon termination defects in glo-4 mutants carrying transgenic 
extrachromosomal arrays that were generated by injecting DNA encoding RIP at a range of 
concentrations as indicated. D) The box in the schematic highlights the region shown below 
that was visualized using muIs32 and epifluorescent microscopy. In wild-type animals, the 
PLM neuron extends its synaptic branch ventrally. Also shown is an example of a glo-4 mutant 
that transgenically overexpressed RIP, in which the PLM synaptic branch is absent 
(arrowhead). E) Quantitation of synaptic branch defects for the indicated genotypes. F) IP with 
an anti-FLAG antibody was used to detect FLAG::RIP in whole worm lysates of representative 
transgenic lines for the indicated genotypes. B, C, E) Shown are the averages of 5 or more 
independent counts (20-30 neurons/count) for each genotype. For transgenes, averages are 
shown for data pooled from 4 or more transgenic lines. Unless noted otherwise, transgenic 
animals were generated by injecting PCR product at 10ng/µL. Error bars represent the 
standard error of the mean, and significance was determined using an unpaired Student’s t 
test. ***P<0.001, *P<0.05, ns = not significant. Scale bars are 10µm. 
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axon (Figure 4-4A). Quantitation showed that overextension occurred with 
increased frequency when RIP was overexpressed (45.4 +/- 2.2%), but not 
mCherry (24.7 +/- 2.8%, Figure 4-4B). Transgenic overexpression of RIP in wild-
type animals also resulted in significant, but lower frequency hook defects 
(Figure 4-4B). Notably, defects caused by overexpression of RIP in wild-type 
animals resulted in a similar frequency of defects as observed in fsn-1 (lf) 
mutants (Figure 4-4B). When we overexpressed RIP or mCherry in fsn-1-/- 
mutants, we observed no differences between the two transgenes with regard to 
the hook phenotype and an extremely small increase in the overextension 
phenotype  (Figure 4-4A and B). Next, we tested the effect of RIP overexpression 
in glo-4-/- animals. glo-4-/- mutants that overexpress mCherry were similar to 
non-transgenic glo-4-/- mutants, and primarily showed overextension defects,  
with lower expressivity of the more severe hook defects (Figure 4-4A and B). In 
contrast, transgenic overexpression of RIP in glo-4-/- mutants resulted in 
enhanced frequency of hook defects, while the expressivity of less severe 
overextension defects was decreased (compare 87.9 +/- 2.1% hook for glo-4 + 
OE RIP with 12.4 +/- 2.4% for glo-4 + OE Cherry, Figure 4-4A and B). To test the 
potency of transgenic RIP, we engineered glo-4-/- animals with transgenic arrays 
that were generated by injecting DNA encoding RIP at a range of concentrations. 
In all cases, including when arrays were constructed at relatively low 
concentrations (0.625ng/µL), we observed strong enhancer effects in the 
expressivity of PLM hook defects (Figure 4-4C). Notably, the enhancer effects 
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caused by overexpression of RIP in glo-4-/- animals were comparable to levels of 
enhancement observed in fsn-1-/-; glo-4-/- double mutants (Figure 4-4B). 
Collectively, these results demonstrate that overexpression of RIP behaves 
genetically like fsn-1 (lf).  
 In wild-type animals, each PLM neuron also extends a single synaptic 
branch that innervates interneurons of the ventral nerve cord  (Figure 4-4D). It 
was previously shown that rpm-1-/- mutants lack a PLM synaptic branch at high 
frequency (Grill et al., 2007; Schaefer et al., 2000). Likewise, fsn-1-/-; glo-4-/- 
double mutants have enhanced frequency of PLM synaptic branch defects 
(Figure 4-4E) (Grill et al., 2007; Tulgren et al., 2011). It was previously noted that 
the absence of the PLM synaptic branch in rpm-1-/- mutants was likely due to a 
failure to form or stabilize PLM synaptic connections, as opposed to defects in 
synaptic branch extension (Schaefer et al., 2000). Thus, this phenotype is likely 
to reflect a defect in synapse formation. 
 Transgenic overexpression of RIP in glo-4-/- mutants primarily resulted in 
the absence of the PLM synaptic branch (Figure 4-4D). Quantitation showed an 
enhanced frequency of PLM synaptic branch defects when RIP was 
overexpressed compared to when mCherry was overexpressed in glo-4-/- 
mutants (compare 77.1 +/- 2.7% for glo-4 + OE RIP with 4.1 +/- 1.7% for glo-4 + 
OE Cherry, Figure 4-4E). When RIP was overexpressed in wild-type animals, the 
frequency of synaptic branch defects was mildly, but significantly, increased 
(compare 21.2 +/- 4.0% for wild-type + OE RIP with 6.6 +/- 1.8% for wild-type + 
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OE Cherry, Figure 4-4E). In contrast, RIP overexpression in fsn-1-/- mutants did 
not significantly change the frequency of synaptic branch defects compared to 
overexpression of mCherry (Figure 4-4E).  
 The two ALM neurons sense anterior soft touch, and terminate extension 
at a precise location in the head of the animal (Figure 4-5A). In wild-type animals, 
the ALM axon terminates well before the anterior tip of the animal’s nose (Figure 
4-5A). Consistent with previous work, we observed ALM axon termination defects 
in glo-4-/- or fsn-1-/- single mutants (Figure 4-5B) (Grill et al., 2007). Categorizing 
ALM axon termination defects into less severe short hooks and more severe big 
hooks facilitated identification of genetic enhancer effects in fsn-1-/-; glo-4-/- 
double mutants (Figure 4-5B) (Tulgren et al., 2011). Previous studies showed 
that ALM axon termination defects in fsn-1-/-; glo-4-/- double mutants occur at 
similar frequency and severity as rpm-1-/- mutants (Grill et al., 2007; Schaefer et 
al., 2000; Tulgren et al., 2011).  
 When RIP was transgenically overexpressed in glo-4-/- mutants, we 
primarily observed big hooks in ALM neurons (Figure 4-5A). The frequency of 
these defects was enhanced compared to glo-4-/- mutants that overexpressed 
mCherry (compare 86.3 +/- 2.1% big hook for glo-4 + OE RIP with 34.0 +/- 3.6% 
for glo-4 + OE Cherry, Figure 4-5B). Overexpression of RIP on a wild-type 
background gave both short hook and big hook phenotypes that were relatively 
low in frequency, but significant (compare 7.0% +/- 1.5% short hook for wild-type 
+ OE RIP with 1.6 +/- 0.8% short hook for wild-type + OE Cherry, Figure 4-5B). 
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Transgenic overexpression of RIP in fsn-1-/- mutants did not alter the frequency 
of ALM axon termination defects compared to overexpression of mCherry (Figure 
4-5B). 
Figure 4-5:  Transgenic overexpression of RIP (RPM-1 D5c) inhibits axon termination in 
the ALM neurons of C. elegans. 
A) A schematic shows the mechanosensory neurons of C. elegans (anterior left, dorsal top), 
which were analyzed using the transgene muIs32 (Pmec-7GFP). The box highlights the region 
of the animal shown below that was visualized using epifluorescent microscopy. Shown is an 
example of normal ALM axon termination in a wild-type animal. Also shown is a glo-4 animal 
that is overexpressing RIP where the ALM axon fails to terminate properly, overextends and 
hooks towards the posterior of the animal (big hook, arrow). The scale bar is 10µm. B) 
Quantitation of ALM axon termination defects for the indicated genotypes (short hook in grey, 
big hook in black). A, B) Shown are the averages of 5 or more independent counts (20-30 
neurons/count) for each genotype. For transgenes, averages are shown for data pooled from 
4 or more transgenic lines. Transgenic animals were generated by injecting PCR products at 
10ng/µL. Error bars represent the standard error of the mean, and significance was 
determined using an unpaired Student’s t test.  ***P<0.001, *P<0.05, ns = not significant 
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 Transgenic overexpression of FLAG::RIP in PLM and ALM neurons had 
strong functional effects,  but we wanted to ensure that changes in transgenic 
RIP expression in different genetic backgrounds did not account for these 
findings. Therefore, we biochemically assessed expression of FLAG::RIP in a 
representative transgenic line for each genotype. As shown in Figure 4-4F, we 
detected expression of transgenic FLAG::RIP in whole worm lysates of all RIP 
transgenic genotypes assessed in our functional analysis. Importantly, we did not 
observe lower expression of FLAG::RIP in genotypes with lower expressivity of 
axon termination defects, such as fsn-1-/- mutants that overexpress RIP. Thus, 
our functional transgenic results are not simply due to variation in expression of 
FLAG::RIP on different genetic backgrounds. We note that FLAG::RIP migrated 
at the expected size of 13.5 kDa, but was detected as a doublet. This was most 
likely the result of protein degradation that occurred during preparation of protein 
extracts from whole animals. Alternatively, the doublet might reflect post-
translational modification of RIP that only occurs in the neurons of C. elegans.  
 In summary, several of our findings are consistent with overexpression of 
RIP acting similar to fsn-1 (lf). 1) Transgenic overexpression of RIP on a wild-
type background resulted in defects that occurred with similar frequency to non-
transgenic fsn-1-/- mutants. 2) We observed no enhancer effects when RIP was 
overexpressed on an fsn-1-/- mutant background. 3) Strong enhancer effects 
occurred when RIP was overexpressed on a glo-4-/- mutant background, and 
enhancer effects occurred with similar frequency to fsn-1-/-; glo-4-/- double 
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mutants. Taken together, these results are consistent with RIP binding to FSN-1 
and inhibiting formation of a functional RPM-1/FSN-1 ubiquitin ligase complex.  
 
4.2.4 Transgenic RIP functions through DLK-1  
Previous studies have shown that the RPM-1/FSN-1 complex functions through 
ubiquitination and inhibition of the MAP3K DLK-1 (Baker et al., 2014; Nakata et 
al., 2005; Wu et al., 2007). To provide further evidence that RIP was functioning 
by inhibiting endogenous FSN-1, we tested if the effects of overexpression of RIP 
were altered by dlk-1 (lf). As shown in Figure 4-6, transgenic overexpression of 
RIP in glo-4-/- mutants resulted in an enhanced frequency of the more severe 
ALM and PLM axon termination defects, as well as PLM synaptic branch defects. 
Enhancer effects caused by RIP overexpression were completely suppressed in 
glo-4-/-; dlk-1-/- double mutants (Figure 4-6). This result was not due to 
suppression of glo-4 by dlk-1, as similar levels of defects were observed in glo-4-
/- single mutants and glo-4-/-; dlk-1-/- double mutants (Figure 4-6). These results 
are consistent with RIP impairing endogenous FSN-1, which functions through 
ubiquitination and inhibition of DLK-1. 
 
4.2.5 RIP function is inhibited by point mutations that block binding to 
FSN-1 
We wanted to test whether point mutations in RIP (D5c), which reduce binding to 
FSN-1 in HEK 293 cells (Figure 4-3C), affected the function of 
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transgenic RIP in worms. To do so, we analyzed PLM axon termination in glo-4-/- 
mutants that carried transgenic extra-chromosomal arrays that overexpressed 
wild-type RIP or RIP point mutants. In order to maximize our ability to detect 
changes in RIP efficacy, transgenic arrays were generated with 2.5ng/µL of PCR 
product encoding RIP, a lower concentration at which maximal effects from RIP 
overexpression were still observed (Figure 4-4C). As shown in Figure 4-7A, 
Figure 4-6:  Effects of transgenic overexpression of RIP (RPM-1 D5c) on axon 
termination are mediated by DLK-1.  
Quantitation of ALM axon termination defects (dark grey, left bar), PLM axon termination 
defects (black, middle bar), and PLM synaptic branch defects (light grey, right bar) for the 
indicated genotypes. Note that defects caused by transgenic overexpression of RIP in glo-4 
mutants are completely suppressed when RIP is overexpressed in glo-4; dlk-1 double 
mutants. Averages are shown for data pooled from 6 or more transgenic lines. Transgenic 
animals were generated by injecting PCR products at 10ng/µL. Error bars represent the 
standard error of the mean, and significance was determined using an unpaired Student’s t 
test.  ***P<0.001, ns = not significant 
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overexpression of wild-type RIP resulted in enhanced PLM axon termination 
defects compared to non-transgenic glo-4-/- animals. In contrast, enhancer 
effects were significantly lower in glo-4-/- mutants that overexpressed RIP point 
mutants (Figure 4-7A). RIP W2239A had the weakest enhancer effect compared 
to wild-type RIP, which suggested that this point mutant was the most 
functionally impaired (Figure 4-7A). RIP D2214A was the point mutant with the 
highest level of enhancement (Figure 4-7A). Thus, RIP D2214A was the least 
functionally impaired point mutant. While CoIP from HEK 293 cells showed that 
point mutation of D2214, F2207, or W2239 strongly impaired binding to FSN-1 
Figure 4-7: Mutations in 
RIP that reduce binding to 
FSN-1 impair the efficacy 
of transgenic RIP. 
Quantitation of PLM axon 
termination defects (hook) 
for the indicated genotypes. 
A) Mutations in RIP that 
impair binding to FSN-1 
reduce the level of RIP 
enhancer effects in glo-4 
mutants. Transgenic animals 
were generated by injecting 
PCR products at 2.5ng/µL. 
B) RPM-1 ΔFBD1 rescues 
defects in PLM axon 
termination caused by rpm-1 
(lf) less efficiently than wild-
type RPM-1. Transgenic 
animals were generated by 
injecting plasmid at 25ng/µL. 
A, B) Averages are shown 
for data pooled from 5 or 
more transgenic lines. 
Significance was determined 
using an unpaired Student’s 
t test.  *P<0.05 **P<0.01 
***P<0.001 
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(Figure 4-3), analysis of axon termination in PLM neurons highlighted the 
functional importance of individual residues in RIP. Presumably this is because 
the neurons of C. elegans are a more physiologically relevant setting, and 
therefore more sensitive to changes in the efficiency of RIP binding to FSN-1. 
Nonetheless, functional analysis of RIP point mutants provided further evidence 
that is consistent with exogenous RIP binding to FSN-1, and inhibiting formation 
of a functional RPM-1/FSN-1 complex. 
 
4.2.6 RPM-1 lacking FBD1 is functionally impaired  
RPM-1 functions though several downstream signaling molecules and pathways, 
one of which is FSN-1 (Baker et al., 2014; Grill et al., 2007; Grill et al., 2012; Liao 
et al., 2004; Nakata et al., 2005; Tulgren et al., 2014). A previous study showed 
that mutating RPM-1 to reduce binding with a single RPM-1 binding protein, 
RAE-1, resulted in a partial loss of RPM-1 function (Grill et al., 2012). This 
prompted us to test whether RPM-1 that lacked FBD1 would be fully functional. 
To do so, we generated transgenic rpm-1-/- mutants that carried 
extrachromosomal arrays and used the native rpm-1 promoter to express wild-
type RPM-1 or RPM-1 lacking FBD1 (RPM-1 ΔFBD1). Consistent with prior 
studies, we observed that transgenic expression of RPM-1 strongly rescued the 
PLM hook defects in rpm-1-/- mutants (Figure 4-7B). In contrast, RPM-1 ΔFBD1 
significantly, but partially, rescued the hook defects in rpm-1-/- mutants (Figure 4-
7B). Thus, RPM-1 ΔFBD1 is only partially functional.  
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4.3 Discussion  
4.3.1 RIP: an in vivo inhibitor of the RPM-1/FSN-1 ubiquitin ligase complex 
Previous studies highlighted the functional relationship between the PHR 
proteins and FSN-1, but the biochemical mechanism of how PHR proteins bind to 
FSN-1 has remained poorly understood (Liao et al., 2004; Saiga et al., 2009; Wu 
et al., 2007). Here, we describe the identification of one mechanism by which 
FSN-1 binds to RPM-1. We show that this interaction is mediated by several key 
motifs in the D5c fragment of RPM-1, which we refer to as RIP when expressed 
recombinantly and as FBD1 (FSN-1 binding domain 1) within the context of the 
overall RPM-1 protein (Figure 4-8). Importantly, the residues in RPM-1 that 
mediate binding to FSN-1 are highly conserved, which suggests that this 
mechanism is likely to be relevant to all PHR proteins.  
 Several of our results suggest that RIP functions as an inhibitor of the 
RPM-1/FSN-1 ubiquitin ligase complex in vivo. 1) Transgenic overexpression of 
RIP caused defects in axon termination that occurred with similar frequency to 
defects caused by fsn-1 (lf) (Figures 4-4 and 4-5). 2) Transgenic overexpression 
of RIP in glo-4 (lf) mutants, but not fsn-1 (lf) mutants, caused enhanced defects 
in axon termination. This is consistent with previous work showing that glo-4 and 
fsn-1 function in parallel pathways to regulate axon termination (Grill et al., 2007). 
3) Enhanced axon termination defects caused by overexpression of RIP in a glo-
4-/- mutant background are suppressed by dlk-1 (lf) (Figure 4-6). This result is 
consistent with previous studies that showed FSN-1 regulates axon termination 
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by inhibiting DLK-1 (Baker et al., 2014; Wu et al., 2007). 4) Point mutations that 
reduce binding of RIP to FSN-1 impair the function of transgenic RIP in vivo 
(Figure 4-7A). 5) Finally, RPM-1 that lacks FBD1 is only partially functional 
(Figure 4-7B). These results provide a body of consistent evidence to support the 
conclusion that transgenically expressed RIP binds to endogenous FSN-1, and 
prevents it from forming a functional complex with RPM-1. RIP now represents 
the first reagent to our knowledge that specifically inhibits the function of a PHR 
ubiquitin ligase complex.  
 A version of RIP that targets mammalian PHR proteins might be a useful 
reagent on several levels. First, viral delivery of RIP or an inducible system for 
RIP expression might be used to study the post-developmental function of the 
ubiquitin ligase activity of PHR proteins. Second, previous work has shown that 
Figure 4-8: Summary of structure-function analysis of RPM-1 and FSN-1.  
Schematic shows the annotated and known functional domains of RPM-1: the RAE-1 
binding domain (RBD), the RAE-1 binding motif boxed within the RBD, and the FSN-1 
binding domain 1 (FBD1). Note that RIP corresponds to the FBD1 region of RPM-1. Our 
structure-function analysis coupled with previous work (Grill et al., 2012) demonstrates that 
RAE-1 and FSN-1 bind at very close, but different locations on RPM-1. Our data support a 
model whereby FSN-1 scaffolds DLK-1 at FBD1 in the center of RPM-1, while the E3 ligase 
domain (RING) of RPM-1 acts independently to ubiquitinate DLK-1.  
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loss of function in rpm-1 or Hiw results in improved axon regeneration 
(Hammarlund et al., 2009; Nix et al., 2011; Xiong et al., 2010). This suggests that 
transgenic overexpression of RIP might improve regeneration. Finally, loss of 
function in PHR proteins in flies and mice dramatically blocks axon degeneration, 
and this is likely to be mediated by Fbxo45 (Babetto et al., 2013; Xiong et al., 
2012). Thus, specifically inhibiting the Phr1/Fbxo45 complex with RIP could have 
potential therapeutic implications for blocking or slowing the progression of axon 
damage following trauma, and possibly in the context of neurodegenerative 
diseases. 
 
4.3.2 Implications for Myc binding to PHR proteins  
We used HEK 293 cells as a heterologous expression system for biochemistry 
with C. elegans proteins, and identified a 97 aa region of RPM-1, annotated as 
FBD1, that is sufficient for binding to FSN-1 (Figure 4-8). We found that 5 highly 
conserved motifs within FBD1 are required for binding to FSN-1. FBD1 is 
contained within a larger domain we previously showed binds to RAE-1 (Grill et 
al., 2012). Our results here show that FSN-1 relies upon a different binding site in 
RPM-1 than RAE-1 (Figure 4-1 and 4-3) (Grill et al., 2012). Thus, while RAE-1 
and FSN-1 are likely to be in close physical proximity, FSN-1 is unlikely to act as 
an adaptor for recruitment of RAE-1 into RPM-1 protein complexes, and vice 
versa. Our biochemical results are consistent with prior genetic and proteomic 
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results, which showed that RAE-1 is not a target of RPM-1 ubiquitin ligase 
activity (Grill et al., 2012; Tian et al., 2011). 
 Our findings also have important implications for the relationship between 
PHR proteins and Myc. Myc was originally found to bind to a region of Pam 
referred to as the Myc binding domain (Guo et al., 1998); more recently this 
domain was shown to also bind the F-box protein Fbxo45 (Saiga et al., 2009). 
The N-terminal half of the Pam Myc binding domain is conserved with Hiw and 
RPM-1, and the C-terminal half of this domain is not conserved. Our results show 
that FBD1, which corresponds with the conserved N-terminal portion of the Myc 
binding domain of Pam, is sufficient for binding to FSN-1. Further, all the 
conserved motifs we identified in FBD1 are required for binding to FSN-1. Thus, 
a likely structural model is that Myc binds to the C-terminal portion of the Myc 
binding domain of Pam, which is not conserved in Hiw and RPM-1. In this 
scenario, Myc would only bind to vertebrate PHR proteins, which is consistent 
with the absence of Myc in proteomic screens for Hiw and RPM-1 binding 
proteins (B. Grill, unpublished observation, and C. Wu, personal communication).  
 An alternative possibility is that FSN-1 might mediate binding of Myc to 
PHR proteins, in which case Myc would be ubiquitinated by the PHR proteins. In 
this scenario, we would have expected mutations in orthologs of Myc to be 
identified in previous suppressor screens with rpm-1 or Hiw (lf), which has not 
occurred to our knowledge. Further, we would not have expected full length Pam 
to bind to Myc in the absence of proteasome inhibitors, which has been observed 
  116 
(Guo et al., 1998). Thus, it is unlikely that FSN-1/Fbxo45 mediates binding of 
Myc to mammalian PHR proteins.  
 
4.3.3 The FSN-1 binding domain of RPM-1 and formation of ubiquitin 
ligase complexes 
Based on our analysis it is unclear whether we have mapped a direct interaction 
site between RPM-1 and FSN-1, or a region of RPM-1 that binds to an adaptor 
protein to recruit FSN-1. Previous work showed that PHR proteins form 
complexes that include FSN-1 and Skp proteins, such as SKR-1 in C. elegans 
(Brace et al., 2014; Liao et al., 2004; Saiga et al., 2009). A Cullin, CUL-1, has 
also been implicated in the RPM-1/FSN-1 ubiquitin ligase complex. However, 
Cullins are absent in the non-canonical Hiw/DFsn and Pam/Fbxo45 ubiquitin 
ligase complexes. Given the structural nature of Skp/Cullin/F-box complexes 
(Zheng et al., 2002), we would expect CUL-1 to bind directly to RPM-1 and act as 
an adaptor for SKR-1, which would then recruit FSN-1. In PHR ubiquitin ligase 
complexes that lack a Cullin, such as Pam/Fbxo45, we would expect Skp1 to 
mediate binding of Fbxo45 to Pam. Interestingly, our biochemical results using 
transgenic C. elegans showed that mutation of a residue, D2214, that is required 
for FBD1 to bind to FSN-1 does not impair binding of full length RPM-1 to FSN-1. 
Thus, while FBD1 is sufficient for binding to FSN-1, it is unlikely to be the only 
site that mediates binding of FSN-1 to RPM-1. There are two molecular models 
that explain this observation. First, CUL-1/SKR-1 might mediate binding of FSN-1 
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to RPM-1 at multiple interaction sites. Alternatively, FSN-1 might bind directly to 
RPM-1 at one location, and CUL-1/SKR-1 could mediate binding of FSN-1 to 
RPM-1 at another location(s).  
 There are several caveats to our experiments in HEK 293 cells that could 
explain why we only identified a single domain that bound to FSN-1. First, 
because we generated 9 individual domains that compose RPM-1, it is possible 
that another FSN-1 interaction site might span a junction between two domains. 
Second, we used a non-native expression system for biochemical mapping. 
Hence, we might fail to detect a second FSN-1 binding site because post-
translational modifications required for the interaction did not occur in 293 cells. 
Alternatively, adaptor proteins (such as Skp or Cul proteins) required for 
interaction between FSN-1 and a second site in RPM-1 might not be expressed 
in these cells or might be unable to bind to C. elegans RPM-1 or FSN-1. 
 The RING-H2 domain of RPM-1 is the catalytic domain that mediates 
ubiquitin conjugation to target proteins (Nakata et al., 2005). FSN-1 did not bind 
to domain 9 of RPM-1, which contains the RING motif. This suggests that FSN-1 
binds to FBD1 of RPM-1 to recruit DLK-1, while the RING-H2 domain at the C-
terminus of RPM-1 is available for ubiquitin conjugation to DLK-1 (Figure 4-8). 
This model is consistent with previous work using HEK 293 cells, which showed 
that a C-terminal fragment of RPM-1 (aa 2970-3766) lacking FBD1 binds to DLK-
1 in the presence of proteasome inhibitors (Nakata et al., 2005). While FBD1 and 
the RING domain are a large distance from one another in the primary protein 
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sequence of RPM-1, it is plausible that these two domains could be in close 
proximity within the tertiary structure of RPM-1. Our findings on RPM-1 and FSN-
1 are consistent with prior work, which showed that other RING-H2 E3 ligases 
bind F-box proteins and ubiquitination targets at locations that are structurally 
distinct from the catalytic RING-H2 domain (Duda et al., 2011; Zheng et al., 
2002).  
 Our results also have implications for the non-canonical ubiquitin ligase 
complexes formed by Hiw and Pam that lack Cullins (Brace et al., 2014; Saiga et 
al., 2009). The Rbx/Cul1/Skp1/Skp2 crystal structure shows that Rbx1, a 
relatively small E3 ligase, is bound by a relatively large Cullin (Zheng et al., 
2002). This results in an arch-like structure that brings the F-box protein Skp2 
and the ubiquitination target into close proximity with Rbx1. Given the large size 
of RPM-1 compared to Rbx1 and the extensive amount of protein sequence 
between the RPM-1 RING domain and FBD1, it is plausible that PHR proteins 
might not require a Cullin to generate a protein complex structure that is 
conducive to target recruitment and ubiquitination.  
  
4.3.4 RIP as a potential therapeutic reagent 
To date, designing specific inhibitors of PHR ubiquitin ligase activity has been 
challenging, due to the large size and complex biochemistry of these proteins. 
While many regions of Hiw have dominant negative effects on synapse formation 
at the neuromuscular junction (Wu et al., 2005), a region in Hiw that specifically 
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regulates FSN-1 function has remained elusive. We now show that RIP 
specifically inhibits the RPM-1/FSN-1 complex in vivo. The conservation of the 
motifs and residues that mediate the interaction between RIP and FSN-1 suggest 
that a mammalian version of RIP might be used to block the function of the 
Pam/Fbxo45 ubiquitin ligase complex in vivo. Previous studies showed that loss 
of PHR protein function mediated by Fbxo45 prevented axon degeneration 
following injury, and in some types of neurons improved axon regeneration 
(Babetto et al., 2013; Hammarlund et al., 2009; Nix et al., 2011; Xiong et al., 
2012; Xiong et al., 2010). Given the role of PHR proteins in axon degeneration 
and regeneration, a reagent such as RIP might have potential as a broad-
spectrum treatment for neurodegenerative diseases. 
 
4.4 Experimental Procedures 
4.4.1 Genetics and axon morphology analysis 
Genetic analysis was performed using the N2 isolate of C. elegans and standard 
procedures (Brenner, 1974). The alleles used in this study included: fsn-
1(gk429), rpm-1(ju44), glo-4(ok623), and dlk-1(ju476). The transgene muIs32 
(Pmec-7GFP) was used for analyzing axon and synaptic branch morphology in 
ALM and PLM neurons. Live, young adult animals were anesthetized using 1% 
(v/v) 1-phenoxy-2-propanol in M9 buffer, and mounted on glass slides with 2% 
agarose. Animals were visualized using a 40x magnification oil-immersion lens 
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and an epifluorescent microscope (Leica CRF 5000). Images were acquired 
using a CCD camera (Leica DFC345 FX). 
 
4.4.2 Cloning 
The 9 domains (D1-9), and subdomains (D5a, b and c) of RPM-1 were amplified 
by RT-PCR from C. elegans total RNA using Superscript III reverse transcriptase 
(Invitrogen). cDNAs were inserted into pCR8 Topo GY, and sequenced to ensure 
they were mutation free. Clones in pCR8 Topo GY were recombined using LR 
recombinase with pBG-GY14 to create pBG-GY189 (GFP-D1), pBG-GY190 
(GFP-D2), pBG-GY191 (GFP-D3), pBG-GY192 (GFP-D4), pBG-GY193 (GFP-
D5), pBG-GY194 (GFP-D6), pBG-GY195 (GFP-D7), pBG-GY196 (GFP-D8), 
pBG-GY197 (GFP-D9), pBG-GY389 (GFP-D5a), pBG-GY412 (GFP-D5b), and 
pBG-GY384 (GFP-D5c). For transgenic expression of RIP (D5c) in C. elegans, 
pBG-GY152 (Prgef-1FLAG GY) was recombined with pBG-GY349 (pCR8 Topo GY 
RIP (D5c)) to generate pBG-GY440 (Prgef-1FLAG::RIP (D5c)). pCZ161 encoding 
full length RPM-1::GFP driven by its native promoter was engineered to contain a 
point mutation D2214A (pBG-190). For point mutagenesis, an HpaI-SpeI 
fragment of RPM-1 was amplified by PCR using pCZ161 as a template and 
inserted into pCR2.1. The HpaI-SpeI fragment was point mutated using 
oligonucleotides with the desired changes and a QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies).  After mutations were confirmed by 
sequencing the mutated HpaI-SpeI fragment was subcloned back into pCZ161 to 
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create pBG-190. Similar mutagenesis procedures were performed on pBG-
GY440 (Prgef-1FLAG::RIP (D5c)) to generate RIP point mutants. These point 
mutations were also sequenced to confirm the accuracy of mutagenesis.  
 
4.4.3 Transgenics 
Transgenic animals were generated by standard microinjection procedures 
(Mello et al., 1991). Transgenic animals were constructed by injecting plasmid of 
interest or PCR product with plasmid encoding Pttx-3RFP (50ng/µL). For dominant 
negative experiments PCR products were amplified by a long PCR kit (Roche) 
and injected at 0.625-10ng/µL as specified. The following plasmids were used as 
templates for long PCR: Prgef-1FLAG::RIP (pBG-GY440) or point mutants, and 
Prgef-1FLAG::mCherry (pBG-GY371). Transgenic animals used for biochemistry 
were generated by injecting plasmids: Prgef-1FLAG::FSN-1 (pBG-GY422) at 
25ng/µL and Prpm-1RPM-1::GFP (pCZ161) or Prpm-1RPM-1::GFP D2214A (pBG-
190) at 25ng/µL into rpm-1; fsn-1 mutants. For coIP of GFP::D5c with 
FLAG::FSN-1 transgenic animals were generated by injecting plasmids: Prgef-
1FLAG::FSN-1 and Prgef-1GFP::D5c (RIP) at 25ng/µL into wild-type animals. 
Notably, expression of FLAG::FSN-1 was higher on a wild-type background than 
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4.4.4 Biochemistry 
For biochemistry in HEK 293 cells or from transgenic C. elegans, FLAG proteins 
were immunoprecipitated (IP) with a mouse monoclonal anti-FLAG antibody (M2, 
Sigma), and immunoblotted with a rabbit polyclonal anti-FLAG antibody (Cell 
Signaling). GFP fusion proteins were precipitated with a mouse monoclonal anti-
GFP antibody (3E6, MP Biomedicals), and immunoblotted with a mixture of 
mouse monoclonal anti-GFP antibodies (Roche). Precipitates were boiled in SDS 
Laemmli Sample Buffer (Biorad), and run on a 3-8% Tris acetate gel (Invitrogen) 
for RPM-1::GFP coIP, or a 4-12% Bis Tris gel  (Invitrogen) for coIP of RPM-1 
domains. Gels were transferred to PVDF membranes in Tris-Acetate transfer 
buffer (16-20 hours at 30 Volts for full length RPM-1::GFP), and immuno-blotted. 
Blots were visualized with HRP conjugated anti-mouse or anti-rabbit secondary 
antibodies, enhanced chemiluminescent reagent (ECL), and x-ray film. When 
necessary due to the size of target proteins, light chain reactive secondary 
antibodies were used (Millipore). Western Lightning Plus ECL was used for HEK 
293 experiments, and Supersignal FemtoWest ECL (Pierce) was used for 
transgenic C. elegans experiments.  
 For experiments with HEK 293 cells, 6cm dishes of cells were transfected 
with a mixture of lipofectamine 2000 (Invitrogen) and a total of 9-11µg of DNA 
that included: plasmid encoding FLAG-FSN-1 (5.2µg DNA), plasmid encoding a 
GFP-RPM-1 domain (3-6µg DNA), and varying amounts of pBluescript (amount 
required to reach total of 9-11µg DNA). A variable amount of DNA was 
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transfected for particular constructs to ensure similar levels of expression. 36-48 
hours after transfection, cells were lysed with 1.0% NP-40 buffer (50mM Tris pH 
7.5, 150mM NaCl, 10% glycerol, 1mM DTT, EDTA-free protease inhibitor pellets 
(Roche), pepstatin, microcystin, NaVO4, NaF, NaMolybdate, and β-
glycerophosphate). 1000 µg of total protein from transfected 293 cells was used 
for individual coIP experiments. Lysates were incubated with primary antibody for 
30 minutes, and precipitated for 4 hours with 10µL of protein G agarose (Roche) 
at 4oC. 
 For biochemistry using transgenic worms, animals containing 
extrachromosomal arrays were propagated using E. coli (strain HB101) on 10cm 
NGM agar plates. Worms were harvested directly off 10cm plates, or moved to 
liquid culture for 1-2 days if larger amounts of material were needed. Animals 
were harvested by centrifugation and washed 3x in M9 buffer. Animals were 
ground using a mortar and pestle, and lysed using sonication and 0.1% NP-40 
lysis buffer (50mM Tris pH 7.5, 0.1% NP-40, 150 mM NaCl, 10% glycerol, 1mM 
DTT, and EDTA-free protease inhibitor pellets). For coIP of RPM-1::GFP with 
FLAG::FSN-1, 20-120mg of total protein from transgenic worm lysates was used. 
For coIP of FLAG::FSN-1 with GFP::D5c from transgenic worm lysates, 25mg of 
total lysate was used. Lysates were incubated with 3µL of M2 (anti-Flag) 
antibody or 3µL of 3E6 (anti-GFP) antibody for 30 minutes, and precipitated for 4 
hours at 4oC with 10µL of protein G agarose. 
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5 Conclusion 
5.1 Summary 
The formation of the nervous system is an intricate process that is controlled by a 
complex network of signaling pathways that allow neurons to extend an axonal 
projection that forms synapses with the correct target. Dynamic interactions 
between the pre- and post-synaptic terminals then provide a way for neurons to 
communicate, propagate information, and engage in plasticity. Understanding 
where and how synapses form is crucial if we are to unravel how the nervous 
system is accurately constructed. The organization of synaptic circuits is 
remarkably well controlled, which suggests inherent mechanisms exist to create 
the identity and connectivity of each neuron in the brain. A limited number of 
conserved molecules and pathways have been shown to both guide axons 
towards their targets, and build functional synapses. While it’s clear that a 
number of events must be coordinated and regulated to form functional 
synapses, the underlying molecular mechanisms remain unknown. The PHR 
proteins, a conserved family of large signaling proteins with ubiquitin ligase 
activity, function in numerous events during neuronal development including: 
axon guidance, axon termination, and synapse formation. Previous findings and 
our own presented here have provided growing evidence that the PHR proteins 
are likely to coordinate and integrate multiple events during neuronal 
development.  
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 The first insight into the physiological function of the PHR proteins came 
from the identification of the invertebrate PHRs, RPM-1 and Hiw, in genetic 
screens looking for abnormal axon and/or synapse morphology. Later studies on 
C. elegans RPM-1 revealed several downstream effectors and signaling 
pathways critical to PHR function (Figure 1-2). In this dissertation, our studies 
provide new insight into the role of the phosphatase PPM-2, and the MLK-1 
pathway in mediating RPM-1 signaling and subsequent effects on axon 
termination and synapse formation (Figure 5-1). Our structure-function analysis 
helped define the biochemical relationship between RPM-1 and FSN-1, and 
further advanced our understanding of how PHR ubiquitin ligase complexes form.  
 In Chapter 2, we show that PHR proteins are more accurate and sensitive 
regulators of DLK that originally thought by demonstrating that they function 
through both phosphatase and ubiquitin ligase mechanisms to inhibit DLK. Using 
mass spectrometry, we identified the PP2C phosphatase PPM-2 as a novel 
RPM-1 binding protein that regulates axon termination and synapse formation. 
Our genetic, transgenic, and biochemical studies indicated that PPM-2 functions 
coordinately with the ubiquitin ligase activity of RPM-1 and the F-box protein 
FSN-1 to negatively regulate DLK-1. We also showed that PPM-2 specifically 
acts on a serine residue of DLK-1 (S874) that has been implicated in regulation 
of full length DLK-1 (DLK-1L) binding to its short inhibitory isoform (DLK-1S).  
 In Chapter 3, we show that a loss of function mutation in kinases of the 
MLK-1 pathway function cell-autonomously in neurons to suppress defects in  
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synapse formation and axon termination caused by rpm-1 loss of function. This 
suppression is much weaker than what is observed with mutations in kinases of 
the DLK-1 pathway, suggesting that RPM-1 functions primarily through the DLK-
1 pathway and secondarily through the MLK-1 pathway to regulate neuronal 
Figure 5-1. Summary of new signaling in the RPM-1 pathway. 
The PP2C phosphatase PPM-2 binds to RPM-1, and negatively regulates signaling through 
the DLK-1 pathway by dephosphorylating a serine residue on DLK-1L (S874). This residue is 
involved in regulation of DLK-1L binding to its short inhibitory isoform DLK-1S. RPM-1 
primarily functions through the DLK-1 pathway and secondarily through the MLK-1 pathway to 
regulate neuronal development. PPM-1 broadly inhibits both the DLK-1 and MLK-1 pathways. 
While FSN-1 mediates DLK-1 ubiquitination, it does not function as the F-box protein to 
negatively regulate the MLK-1 pathway. A conserved 97-amino acid region of RPM-1 (FBD1) 
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development. Our genetic and transgenic analysis also show that the 
phosphatase PPM-1 is a potential inhibitor of kinases in the MLK-1 pathway, 
while PPM-2 seems to be more specific and only inhibits DLK-1.  
 Finally in Chapter 4, we have demonstrated that RPM-1 uses a conserved 
mechanism to bind FSN-1 that is independent of the domain in RPM-1 that has 
catalytic ubiquitin ligase activity. We found a single domain centrally located in 
RPM-1 that is sufficient for binding to FSN-1, and further refined this to a 
conserved 97-amino acid region of RPM-1. Mutagenesis identified several 
conserved motifs and individual amino acids that mediate this interaction. 
Transgenic overexpression of this small fragment of RPM-1 causes defects in 
axon termination and synapse formation similar to loss of function in fsn-1. These 
defects were suppressed by loss of function in dlk-1 and were alleviated by point 
mutations that reduce binding to FSN-1. Together, our biochemical and genetic 
analysis has led to the identification of the first in vivo inhibitor of the RPM-
1/FSN-1 ubiquitin ligase complex. 
 
5.2 Future directions 
5.2.1 Regulation of DLK-1 activation 
Our study on the PP2C phosphatase PPM-2 has provided the first evidence that 
PHR proteins are able to regulate a single target through multiple independent 
mechanisms.  We proposed a model whereby RPM-1 inhibits local activation of 
the MAP3K DLK-1 through PPM-2 and long-term regulation of DLK-1 through 
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ubiquitination (Figure 5-1). In worms, two isoforms of DLK-1 exist, and a single 
hexapeptide motif in full length DLK-1 (DLK-1L) regulates binding to a short 
inhibitory isoform (DLK-1S) (Yan and Jin, 2012). This conserved hexapeptide 
contains two serine residues (S874 and S878), and phosphomimetic 
manipulations suggest that the charge state of this hexapeptide tightly regulates 
the balance between inactive DLK-1L/S heteromeric complexes and active DLK-
1L homomeric complexes (Yan and Jin, 2012). Our study shows that this motif is 
the site of PPM-2 inhibitory activity, but with PPM-2 specifically 
dephosphorylating the S874 residue of DLK-1L (Figure 5-1). However, we still do 
not understand the complete mechanism by which dephosphorylation of this 
motif affects binding of DLK-1S to DLK-1L. While binding of these two isoforms 
was not altered in ppm-2 mutants, DLK-1S shows greatly reduced binding to a 
phosphomimetic DLK-1L when both serine residues of the hexapeptide are 
mutated to mimic a phosphorylated state (S874E, S878E) (Yan and Jin, 2012).  
 Future biochemical and genetic experiments will be necessary to test if 
PPM-2 affects the binding of DLK-1L to DLK-1S, or directly regulates DLK-1L 
activation independent of DLK-1S. Several experiments could be helpful in 
testing which of the two models is correct. For example, we could perform single 
phosphomimetic point mutations at S874 or S878 residues of DLK-1L to test if 
modification of one or both residues affects binding to DLK-1S. If only S878 
mediates binding to DLK-1S then we would conclude that phosphorylation of 
both S874 and S878 are required for DLK-1L activation, but phosphorylation of 
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each residue mediates an independent mechanism of inhibition.  
 Furthermore, if experimental evidence indicates that DLK-1L is regulated 
by phosphorylation at both S874 and S878, it will be critical to understand how 
DLK-1L is activated and inactivated. Since its identification and characterization, 
autophosphorylation of mammalian DLK was observed (Holzman et al., 1994; 
Mata et al., 1996), and later studies showed that dimerization initiates this 
autophosphorylation and subsequent activation of DLK catalytic activity (Nihalani 
et al., 2000; Nihalani et al., 2001). Despite this initial progress, the mechanisms 
that govern activation of DLK remain poorly understood. In addition, recent 
studies have revealed numerous phosphorylation sites present in mammalian 
DLK (Huntwork-Rodriguez et al., 2013), suggesting that the complexity of this 
regulatory system could be significantly expanded in mammals. Our discovery in 
worms that PPM-2 inhibits DLK-1L by direct dephosphorylation at S874, and the 
discovery of DLK-1S provide a good start in understanding how DLK-1L is 
inhibited and how dimerization may occur. However, identification of kinases and 
other phosphatases that regulate phosphorylation at S874 and/or S878 of DLK-
1L will be helpful in further unraveling how DLK-1L is activated and inactivated. 
 
5.2.2 PP2C phosphatase function outside of neuronal development 
While DLK-1 plays an important role in neuronal development, it is also essential 
for axon regeneration in C. elegans, Drosophila, and mice (Hammarlund et al., 
2009; Itoh et al., 2009; Shin et al., 2012; Xiong et al., 2010; Yan et al., 2009). 
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Importantly, loss of function in C. elegans rpm-1 and Drosophila Highwire, or 
overexpression of DLK-1 leads to improved axon regeneration (Hammarlund et 
al., 2009; Nix et al., 2011; Xiong et al., 2010; Yan et al., 2009). Loss of function in 
fsn-1 also results in improved regeneration (Hammarlund et al., 2009). These 
studies demonstrate that relieving inhibition on or activating the DLK-1 pathway 
promotes axon regeneration, particularly in older adult C. elegans where 
regeneration is much less robust. Additionally, another MAPK pathway, the MLK-
1/MEK-1/KGB-1(JNK), functions together with the DLK-1 pathway to regulate 
axon regeneration (Nix et al., 2011). These studies suggest that potential 
therapies aimed at improving recovery after traumatic axotomy could potentially 
target either of these pathways.  
 Our findings that PPM-2 specifically regulates the DLK-1 pathway and 
PPM-1 broadly inhibits both the DLK-1 and MLK-1 pathway during neuronal 
development (Figure 5-1), suggests that these phosphatases may also play a 
post-developmental role in axon regeneration. Our findings predict that increased 
DLK-1 and/or MLK-1 activity in ppm-2-/- and/or ppm-1-/- animals could result in 
improved regenerative capacity compared to wild-type animals. In addressing 
this possibility, several important considerations from our developmental 
understanding of DLK-1 and MLK-1 signaling should be taken into account. 1) A 
combination of loss of function in fsn-1 with either ppm-2 or ppm-1 might be 
necessary to see improved regeneration, as these genes function in parallel 
pathways to regulate DLK-1. 2) A prior study showed that older animals have 
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poor regeneration that is more sensitive to increased levels of DLK-1 activity 
(Hammarlund et al., 2009). Therefore, with PPM-2 being a partial regulator of 
DLK-1 activity, the possible effects of PPM-2 on regeneration may be more 
noticeable in older animals. 3) Crosstalk between the DLK-1 and MLK-1 
pathways exists (Nix et al., 2011). Therefore, inhibiting a broad regulator of both 
pathways, such as PPM-1, may be a better therapeutic approach than inhibiting 
a specific regulator of just one of the MAPK pathways, such as PPM-2. On the 
other hand, inhibition of the MAP3Ks of the MAPK cascades may prevent signal 
amplification, therefore limiting the cellular response to axonal injury. In this case, 
inhibitors of the highest kinases of the MAPK cascades, DLK-1 and/or MLK-1 
may prove to be the best therapeutic targets for improving regeneration. 
Exploring the possible role of the PP2C phosphatases in regeneration is 
worthwhile, as the enzymatic activity of these phosphatases may be particularly 
amenable to pharmaceutical intervention.  
 
5.2.3 Crystal structure of the PHR ubiquitin ligase complex    
The PHR proteins are larger than 400 kDa, and the large size and complex 
biochemistry of these proteins has limited structure-function analysis. Some 
progress was made with the discovery that the F-box protein Fbxo45 binds to a 
fragment of Pam that was previously shown to bind to Myc (Saiga et al., 2009). 
This dissertation describes further structure-function analysis in which we 
showed the conserved FSN-1 binding domain 1 (FBD1) in RPM-1 was sufficient 
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for binding to FSN-1 in vivo in worm neurons and in HEK 293 cells (Figure 5-1). 
FBD1 is a conserved domain in all PHR proteins suggesting it is likely to be a 
conserved mechanism by which PHR proteins bind to F-box proteins. We 
showed that transgenic overexpression of recombinantly expressed FBD1 (RIP) 
in the neurons of worms results in dominant negative effects on synapse 
formation and axon termination, which are consistent with fsn-1 loss of function. 
RIP represents the first specific inhibitor of the PHR ubiquitin ligase complex. 
Given the role of PHR proteins in axon degeneration and regeneration, RIP 
represents a potential therapeutic treatment for neurodegenerative diseases 
(Babetto et al., 2013; Hammarlund et al., 2009; Nix et al., 2011; Xiong et al., 
2012; Xiong et al., 2010). However, further structure-function analysis of the PHR 
ubiquitin ligase complex will prove valuable for a number of reasons. 1) While 
FBD1 is sufficient for binding to FSN-1, it is unlikely to be the only site that 
mediates binding of FSN-1 to RPM-1. Our recent findings indicate that in addition 
to FBD1, several other sites mediate binding of FSN-1 to RPM-1. These sites 
were not detected when we used a heterologous expression system, HEK 293 
cells, for biochemical mapping of FSN-1 binding to different domains in RPM-1. 
2) Previous work has showed that PHR proteins form complexes that include 
FSN-1 and Skp proteins (Brace et al., 2014; Liao et al., 2004; Saiga et al., 2009). 
A Cullin has been implicated in the RPM-1/FSN-1 ubiquitin ligase complex, which 
is absent in the non-canonical Hiw/DFsn and Pam/Fbxo45 ubiquitin ligase 
complexes. Pursuing further structure-function with Pam, Skp1, and Fbxo45 will 
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allow us to determine if FBD1 of Pam mediates direct binding to Fbxo45 or Skp1. 
Further, we will assess whether the FBD1 of Pam is a conserved site of F-box 
binding for the PHR proteins. Structure-function analysis with Pam, Skp1, and 
Fbxo45 will ultimately lay the groundwork for generation of crystal structures that 
definitively address the nature of this non-canonical ubiquitin ligase complex. 
Hopefully, this type of comprehensive biochemical analysis will allow 
development of a small molecule that specifically impairs the ubiquitin ligase 
activity of the Pam/Skp1/Fbxo45 complex, and potential value in treating a range 
of neurodegenerative diseases.  
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